Development of methodology for the determination of catecholamines, indoleamines, and related hydroxylating enzymes. by Wong, Peter Kwei-yen,
INFORMATION TO USERS
This was produced from a copy of a document sent to us for microfîlming. While the 
most advanced technological means to photograph and reproduce this document 
have been used, the quality is heavily dependent upon the quality of the material 
submitted.
The following explanation of techniques is provided to help you understand 
markings or notations which may appear on this reproduction.
1. The sign or “target” for pages apparently lacking from the document 
photographed is “Missing Page(s)”. If it was possible to obtain the missing 
page(s) or section, they are spliced into the fîlm along with adjacent pages. 
This may have necessitated cutting through an image and duplicating 
adjacent pages to assure you of complete continuity.
2. When an image on the Him is obliterated with a round black mark it is an 
indication that the film inspector noticed either blurred copy because of 
movement during exposure, or duplicate copy. Unless we meant to delete 
copyrighted materials that should not have been filmed, you will find a 
good image of the page in the adjacent frame.
3. When a map, drawing or chart, etc., is part of the material being photo­
graphed the photographer has followed a definite method in “sectioning” 
the material. It is customary to begin filming at the upper left hand comer 
of a large sheet and to continue from left to right in equal sections with 
small overlaps. If necessary, sectioning is continued again—beginning 
below the first row and continuing on untU complete.
4. For any illustrations that cannot be reproduced satisfactorily by 
xerography, photographic prints can be purchased at additional cost and 
tipped into your xerographic copy. Requests can be made to our 
Dissertations Customer Services Department.
5. Some pages in any document may have indistinct print. In all cases we 




3(30 N. ZE E B  RO A D , ANN A R B O R ,  Ml 4 8 1 0 6  
18 B E D F O R D  ROW, LO NDON WC1 R 4 E J ,  EN G L A N D
8107969
WONG, Pe t e r  K w ei-Y e n
DEVELOPMENT OF METHODOLOGY FOR THE DETERMINATION OF 
CATECHOLAMINES, INDOLEAMINES, AND RELATED HYDROXYLATING 
ENZYMES
The University o f Oklahoma PH.D. 1980
University 
Microfilms
internetionsi 300 N. Zeeb Road. Ann Arbor, MI 48106
THE UNIVERSITY OF OKLAHOMA 
GRADUATE COLLEGE
DEVELOPMENT OF METHODOLOGY FOR THE 
DETERMINATION OF CATECHOLAMINES, 
INDOLEAMINES, AND RELATED 
HYDROXYLATING ENZYMES
A DISSERTATION 
SUBMITTED TO THE GRADUATE FACULTY 




PETER KWEI-YEN WONG 
Norman, Oklahoma 
1980
DEVELOPMENT OF METHODOLOGY FOR THE 
DETERMINATION OF CATECHOLAMINES, 









The author wishes to express his most sincere 
appreciation and deepest gratitude to Dr. C. LeRoy Blank 
for his guidance, assistance and encouragement during the 
course of this work.
Special thanks are also extended to Drs. Leon 
Ciereszko, Glenn Dryhurst, Sam Sofer and Richard Taylor 
for serving on the advisory committee. Their valuable 
advice and suggestions are gratefully acknowledged.
The author wishes to express his sincere thanks 
to fellow graduate and undergraduate students: Mike
Bulawa, Peter Lin and Lorrie Greene for their assistance, 
friendship and useful discussions.
The financial support in the form of teaching 
assistantships from the University of Oklahoma and a research 
assistantship from NIMH/DHEW/PHS are gratefully acknowledged.
Special thanks also goes to Ms. Nancy Nielsen for 
her efficient help in typing this manuscript.
The author is most indebted to his loving wife, 
Sui-Ha, for her patience, understanding and encouragement 
during the course of graduate work.
iii
Finally, the author wishes to dedicate this to the 
memory of his late parents who helped to lay the foundation 





LIST OF T A B L E S ........................................  ix
LIST OF I LLUSTRATIONS.................................. xiii
Chapter
1. GENERAL INTRODUCTION ........................  1
I. Tyrosine Hydroxylase and Tryptophan
Hydroxylase...............................  1
A. Background...........................  1
B. Kinetic Properties ..................  5
C. Enzyme Preparations ................  8
D. Regulation and Control of Tyrosine
and Tryptophan Hydroxylase .........  11
E. Analytical Procedures .............. 13
II. 5-Hydroxytryptamine (5-HT, Serotonin) . 17
A. General Background ..................  17
B. Analytical Determination ............ 19
III. Liquid Chromatography with Electro­
chemical Detection......................  21
IV. References...............................  26
2. DETERMINATION OF TYROSINE HYDROXYLASE 
ACTIVITY BY LIQUID CHROMATOGRAPHY WITH 
ELECTROCHEMICAL DETECTION .................. 33
V
TABLE OF CONTENTS (continued)
Chapter Page
I. Assay Procedure for vitro Tyrosine
Hydroxylase Activity ........................  33
A. Introduction.............................  33
B. Development of Assay Procedure .........  34
1. Overview.............................  34
2. Materials and M e t h o d s .............. 35
3. Chromatographic Conditions .........  43
4. Isolation Procedure ................  47
5. Optimization of Incubation
Parameters......................   49
6. Minimizing Blank (Noise) Levels . . 68
7. Summary of R e s u l t s ..................  74
C. Application of the Developed Procedure .
for vitro Tyrosine Hydroxylase 
Activity. Determination of TH Activity 
in Mouse Brain Striatum After Sacrifice
by Microwave Irradiation ................ 79
1. Background...........................  79
2. P r o c e d u r e ...........................  80
3. Results and Discussion..............  81
II. Simultaneous Determination of ^  vivo TH
Activity and Endogenous Catecholamines . . , 83
A. Introduction.............................  83
B. Materials and M e t h o d s ..................  84
vi
TABLE OF CONTENTS (continued)
Chapter Page
C. Results and Discussion..............  86
III. References................................ 95
3. DETERMINATION OF TRYPTOPHAN HYDROXYLASE 
in vitro BY LIQUID CHROMATOGRAPHY WITH
ELECTROCHEMICAL DETECTION .................  97
I. Introduction  ....................... 97
II. Development of the A s s a y ................. 98
A. M a t e r i a l s ...........................  98
B. Data Treatment....................... 101
C. Initial Procedure ..................  101
D. Liquid Chromatographic Conditions . 102
E. Isolation Studies ..................  108
F. Optimization of Incubation
Parameters........................... 112
G. Final P r o c e d u r e ..................... 128
III. References
4. A RAPID AND SENSITIVE PROCEDURE FOR THE 
DETERMINATION OF SEROTONIN IN MOUSE BRAIN
T I S S U E ........................................  132
I. Introduction.............................  132
II. Materials and M e t h o d s ............   133
A. M a t e r i a l s ...........................  133
B. Routine Procedure ..................  135
C. Data Treatment....................... 136
vii
TABLE OF CONTENTS (continued)
Chapter Page
III. Development of Procedure................  138
A. Chromatographic Conditions ......... 138
B. Attempted Whole Brain Analysis . . .  140
C. Investigation of Homogenizing
M e d i u m ...............................  143
D. Sonication Effects .................. 147
E. L i n e a r i t y ........................... 151
F. Final P r o c e d u r e ....................  152
IV. Examination of Possible post mortem
Alterations of Serotonin in Mouse





1.1 Substrate Specificity of Mammalian
Hydroxylating Enzymes ..........................  9
2.1 Percentage Recovery of Dopa and DHBA After
Alumina Adsorption...............................  48
2.2 The Effect of Concentration of Acetate
Buffer on TH Activity..........................  51
2.3 The Effect of Catalase on TH Activity......... 55
2.4 The Effect of Iron(II) on TH Activity......... 55
2.5 The Effect of DMPH^ on TH Activity ...........
2.6 The Effect of 6-MPH^ on TH Activity ...........
2.7 The Effect of Incubation Temperature on
TH Activity...................................... 63
2.8 The Effect of Shaking Rate and Position of
Incubation Tube on the Rate of Dopa Production 63
2.9 The Effect of Tyrosine Concentration on
Blank Values and TH activity....................  67
+22.10 The Effect of Fe and Tyrosine on Blank
V a l u e s ...................    71





LIST OF TABLES (continued)
TABLE PAGE
2.12 Summary of Optimization of the TH Assay. . . .  75
2.13 Comparison of Sensitivity Between LC/EC
and Radioassay.................................  77
2.14 Stability of Accumulated Dopa after NSD-1034
and M T ..........................................  89
2.15 Stability of Accumulated Dopa after NSD-1034
and a - M T ........................................  89
2.16 Stability of Accumulated Dopa after NSD-1034
and a - M T ........................................  90
2.17 Stability of Accumulated Dopa after NSD-1015
and M T ..........................................  90
2.18 Stability of Accumulated Dopa after NSD-1015
and M T ..........................................  91
2.19 Catecholamine Levels in Mouse Brain at Various
Times after NSD-1034 ........................... 94
3.1 Recovery of 5-HTP and NM-5-HT from Incubation
Mixtures after Isolation with AG 50W-X2 Cation 
Exchange R e s i n ...............   112
3.2 Effect of Fe^^ and Ca^^ on TPH Activity and
Blank V a l u e s ...................................  114
3.3 Summary. Optimization of TPH Incubation
Parameters...................................... 129
4.1 Reagents Used in the Determination of Serotonin
in Mouse Whole Brain and Brain Parts .........  137
X
LIST OF TABLES (continued)
TABLE PAGE
4.2 Whole Mouse Brain 5-HT Levels Reported by
Various Workers .................................  142
4.3 The Effect of Acid Concentration in the 
Homogenizing Medium on Whole Mouse Brain
5-HT L e v e l s ...................................... 144
4.4 Composition of Samples Used to Determine 
the Percent Recovery of 5-HT and NM-5-HT
from Different Homogenizing Mediums .........  146
4.5 The Effect of Ultrasonic Treatment on 5-HT
and N M - 5 - H T .................................... 149
4.6 The Effect of Sonication Time on Peak 
Heights and Peak Height Ratio for 5-HT and
NM-5-HT in Mouse Brain Tissue ..............  150
4.7 Composition of Sample Used to Investigate 
the Percent Recovery of 5-HT and NM-5-HT
in the Absence and Presence of Brain Tissue
After Sonication...............................  150
4.8 Percent Recovery of 5-HT and NM-5-HT in 
the Presence and Absence of Brain Tissue
after Ultrasonic Treatment ....................  152
4.9 5-HT Levels of Whole Mouse Brain after 
Sacrificing by Microwave Irradiation and 
Decapitation .................................... 155
xi
LIST OF TABLES (continued)
TABLE PAGE
4.10 5-HT Levels of Mouse Brain Parts after
Different Methods of Sacrificing .............  155
4.11 T-test for Results Listed in Table 4.10 . . .  156
Xll
LIST OF ILLUSTRATIONS 
FIGURE PAGE
1.1 Biosynthetic Pathways for Catecholamines
and Indoleamines ...............................  3
2.1 Low Resolution Chromatogram Used in
Previous TH Assay...............................  44
2.2 High Resolution Chromatogram Used in
Current TH A s s a y ...............................  46
2.3 Relationship Between the Peak Height Ratio 
of Dopa and DHBA and the Amount of Dopa
Added in the Alumina Adsorption Procedure . . 50
2.4 The Effect of Buffer pH on TH Activity . . . .  52
2.5 The Effect of Various Phosphate Concen-
traions on TH A ctivity......................... 54
2.6 The Effect of Different Dopa Decarboxylase
Inhibitors on TH Activity  .................. 57
2.7 The Effect of 6-MPH^ on the Rate of
Formation of Dopa...............................  59
2.8 The Effect of 2-Mercaptoethanol on TH
A c t i v i t y ........................................  62
2.9 The Effect of L-Tyrosine on the Rate of Dopa
Formation........................................  65
xiii
LIST OF ILLUSTRATIONS (continued)
FIGURE PAGE
2.10 The Effect of Incubation Time on TH Activity . 66
2.11 Dopa Formed as a Function of Added Brain 
Homogenate...................................... 69
2.12 TH Activity as a Function of Microwave 
Irradiation T i m e ...............................  82
2.13 Time Course of Dopa Accumulation in Mouse
Brain after Treatment with NSD-1034   87
2.14 The Effect of TH Inhibition on Dopa 
Accumulated after NSD-1034 (or NSD-1015)
T r e a t m e n t ...................................... 92
3.1 A Typical Chromatogram for a TPH Assay by 
Direct Injection into a Vydac Cation Exchange 
C o l u m n ..........................................  104
3.2 The Use of Column Switching to Separate
and Discard the 6-MPH^ in a TPH Assay . . . .  106
3.3 Peak Height Ratio of 5-HTP to NM-5-HT as a 
Function of the Amount of 5-HTP Added Prior
to AG 50W-X2 Isolation........................  110
3.4 A Typical Chromatogram for the TPH Assay 
Using a Reverse-Phase, Microparticle
C o l u m n ..........................................  Ill
3.5 The TPH Activity as Function of the pH
of the Incubation M e d i u m ......................  116
xiv '
LIST OP ILLUSTRATIONS (continued)
FIGURE PAGE
3.6 The Effect of 2-Mercaptoethanol on TPH
Activity.......................................... 117
3.7 The Effect of NSD-1015 on TPH Activity . . . .  119
3.8 The Effect of the Cofactor on the Rate of
5-HTP Formation...................................  120
3.9 The Effect of Catalase on TPH Activity . . . .  121
3.10 The Effect of the Substrate Concentration on
the Rate of 5-HTP Formation....................  122
3.11 The Amount of 5-HTP Formed as a Function of
the Incubation T i m e ........................... 124
3.12 The Effect of the Preincubation Time on
TPH Activity.....................................  125
3.13 The Effect of the Incubation Temperature
on TPH A c t i v i t y ................................. 126
3.14 The Amount of 5-HTP Formed as Function of
the Volume of Brain Homogenate Added to
the Incubation Mixture ........................  127
4.1 A Typical Chromatogram Obtained From a
Whole Mouse Brain 5-HT A s s a y ...................  139
4.2 A Typical Chromatogram Obtained During the 
Determination of 5-HT in Mouse Brain Striatum 141
4.3 The Effect of Different Concentrations of 
Various Homogenizing Acids on the Recovery
of 5-HT............................................ 145
XV
LIST OF ILLUSTRATIONS (continued)
FIGURE PAGE
4.4 Chromatograms from Whole Mouse Brain
5-HT Assays......................................  148
4.5 The Peak Height Ratio of 5-HT to NM-5-HT 
Versus the Amount of 5-HT Added to the




I . Tyrosine Hydroxylase and Tryptophan Hydroxylase
A. Background. During the past few decades, a large 
number of studies have been undertaken in an attempt to more 
fully understand the adrenergic and serotonergic nervous 
systems in the mammalian brain. These systems utilize the 
catecholamines, namely, dopamine (DA) and norepinephrine 
(NE), and the indoleamine, 5-hydroxytryptamine (5-HT, 
serotonin), as neurotransmitters. The development of highly 
specific histochemical techniques for observation of these 
species have placed these transmitters in a very unique 
position in neurobiology. Such techniques have allowed a 
detailed mapping of their respective pathways in the central 
nervous system. In conjunction with a variety of biochemical 
and pharmacological investigations, specific pathways have 
been demonstrated to have a definite relationship to both 
animal and human behavioral responses. Other studies have 
very strongly implicated the involvement of these biogenic 




The biosynthesis of these neurochemical transmitters, 
as shown in Figure 1.1, exhibits many common features among 
the two, separate pathways. Both pathways indicate hydroxyla­
tion of a dietary amino acid (1), followed by decarboxylation. 
The appropriate enzymes are specifically located in the 
catecholaminergic and serotonergic cells, respectively. 
Additionally, noradrenergic cells contain dopamine-g-hydroxy­
lase, the enzyme which catalyzes the conversion of dopamine 
into norepinephrine. The decarboxylation in both pathways 
is commonly assumed to be affected by the same, non-specific 
aromatic amino acid decarboxylase. However, decarboxylation 
may be effected by separate enzymes as indicated in Figure 
1.1. The conversions of L-tyrosine to L-dopa and L-tryptophan 
to 5-hydroxytryptophan by their respective hydroxylating 
enzymes are universally accepted to represent the rate 
limiting steps in the biosynthesis of these transmitters 
(2,3). Therefore, considerable attention has been focused 
on these particular enzymes following their initial dis­
covery and isolation some fifteen years ago (2). The 
activities of these enzymes are, relatively speaking, very 
low. Thus, investigations of their location and properties 
demand utilization of highly sensitive analytical procedures.
Tyrosine hydroxylase (TH) is widely distributed in 
animal tissues. It is most prominent in the adrenal medulla, 
the spleen, the peripheral sympathetic nervous system, and 
the central nervous system (6,10). In the central
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nervous system, TH is not homogeneously distributed and 
is found to decrease in the following regional sequence; 
caudate nucleus >hypothalamus > thalamus>midbrain>medulla 
oblongata>cerebral cortex>cerebellum (1). As for sub- 
cellular distribution, some TH activity is found in cell 
bodies, but the majority is confined to the nerve terminals 
or varicosities of catecholamine-containing cells. There 
is also considerable evidence that the enzyme exists in 
two distinct physical forms, soluble and membrane-bound
(7,8). The soluble form is present largely in cell bodies 
while the membrane-bound form is localized primarily in the 
nerve terminal regions (16).
Tryptophan hydroxylase (TPH) is not as widely dis­
tributed in mammals as is TH. It has been found, however, 
in fairly large concentrations in the gastrointestinal 
tract (smooth muscle), the pineal gland, and the central 
nervous system. As with most cerebral enzymes, there are 
marked differences in the regional distribution of tryptophan 
hydroxylase in the central nervous system. The highest 
activities were reported for the hypothalamic and thalamic 
regions, with the midbrain and medulla exhibiting considerable, 
but lesser activities (17,18). The cortices and cerebellum 
show very low levels of tryptophan hydroxylation. Most 
of the enzyme activity from brain stem is recoverable in 
the 30,OOOxg supernatant following homogenization in a 
hypotonic, 0.05 M tris-acetate buffer (pH 7.4-7.6), but
5
not in an isotonic sucrose (0.32 M) supernate (19). As with 
TH, the existence of two distinct forms of TPH has also 
been suggested (20). TPH from the brain appears to be 
predominately soluble (19), although Knapp and Mandell 
have reported that a small portion of the enzyme is found 
in a particulate fraction. The ratio of particulate to 
soluble TPH varies from region to region, with the highest 
value being obtained in those areas with the greatest number 
of serotonergic nerve endings (20).
Neither TPH nor TH have been isolated as homogeneous 
entities. The best preparation of tyrosine hydroxylase 
has been obtained from adrenal medulla (11). It is about 
40% pure and appears to be at least similar to, if not 
identical with, the TH found in catecholaminergic neurons 
(12). TPH has been obtained from a number of different 
tissues, but has not yet been extensively purified. Several 
attempts at purifying this enzyme from central nervous system 
tissues have yielded only partial success (13,14).
B. Kinetic properties. Much of the mechanistic and 
kinetic information obtained for TH and TPH has been pre­
ceded and greatly aided by the work of Kaufman and coworkers 
(21) on a related hepatic enzyme, phenylalanine hydroxylase. 
These workers have clearly established phenylalanine hydroxy­
lase as a mixed function oxidase requiring both molecular 
oxygen and a reduced pterin, later identified as tetrahydro-
biopterin. It now appears that both tyrosine and tryptophan 
hydroxylation proceed by similar mechanisms. The reduced 
pterin cofactor for both tyrosine and tryptophan hydroxylation 
in vivo is also believed to be tetrahydrobiopterin (22). 
However, 6 ,7-dimethyl-5,6,7,8-tetrahydropterin (DMPH^) 
and 6-methy1-5,6,7,8-tetrahydropterin (6-MPH^) are commonly 
used for ^  vitro hydroxylation due to ease of handling and 
commercial availability. Kinetic data for tyrosine hydroxyla­
tion are consistent with the following individual steps
(3,9) :
1. Reduction of an oxidized form of the enzyme by 
the reduced pterin cofactor and dissociation 
of the oxidized pterin,
2. Formation of a complex with the substrate,
3. Aerobic oxidation of the enzyme-bound tyrosine 
producing 3 ,4-dihydroxyphenylalanine (dopa) and 
the oxidized formed of the enzyme.
This can be summarized as:
E + DMPH^ EH2 + DMPHg
02EH2 + Tyr [EH2 *Tyr] — -— ) E + dopa + H2O
Metal ions, particularly iron(II), may play an im­
portant role in these hydroxylation reactions. A wide 
variety of assay conditions used by different workers have 
alternately demonstrated both dependence and lack of de­
pendence upon added ferrous ion for optimal 3̂  vitro activity. 
Stimulation of TH or TPH activity by ferrous ion appears
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to be dependent on the degree of purification of the
enzymes, the nature of the pterin cofactor used (2), and
the source of the enzyme preparations (4). The role of
ferrous ion as a possible cofactor in either of these
hydroxylation reactions is, thus, currently a controversial
topic. One possible explanation of the observed stimulation 
+2by Fe is the known ability of this species to destroy
to be generated during nonenzymatic oxidation 
of the reduced pterin cofactor (5). This explanation is 
supported by the fact that iron can often be replaced by 
catalase, an enzyme which rapidly decomposes ^ 2^ 2 ’
Completely valid observations on the kinetic pro­
perties of enzymes can, of course, be obtained only from 
pure preparations. However, much valuable information has 
been obtained from the partially purified preparations of 
TH and TPH. The work of Kaufman and his associates (5,14,
15) has shown a marked interdependence of the cosubstrates 
(amino acid, reduced pterin and oxygen) with regard to 
their kinetic constants. For example, with brain tryptophan
hydroxylase, the value for tryptophan is seen to shift 
-4 -5from 3x10 M to 5x10 M as one changes the cofactor from 
6,7-dimethyl-5,6,7,8-tetrahydropterin to tetrahydrobiopterin.
Based upon multiple investigations of the physical 
properties of these hydroxylating enzymes, we are now able 
to conclude that mammalian tissues contain three distinct, 
but related enzymes. These three systems, summarized
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in Table 1.1, are involved in the hydroxylations of, re­
spectively, phenylalanine, tyrosine, and tryptophan.
With the exception of tryptophan hydroxylase, none of these 
enzymes is capable of exhibiting complete substrate specifi­
city with respect to the other two substrates.
C. Enzyme preparations. Depending on the specific 
nature of the investigation to be undertaken, there are 
two major different approaches one may select in preparing 
either TH or TPH. By employing an isotonic homogenizing 
medium and a glass/Teflon homogenizing apparatus with a 
moderate clearance, typically 0.01 mm, the nerve cell 
endings will be first separated from the cell bodies and 
then their membranes reseal to form synaptosomes. This 
synaptosomal preparation preserves the architectural in­
tegrity of the tissue to be investigated and contains a 
relatively intact hydroxylating system. Harris et al. (35) 
used such an approach in a study of tyrosine hydroxylase. 
They claimed that this preparation was relatively simple 
to use since it does not require the addition of exogenous 
cofactor. Presumably, the natural cofactor is contained 
within the synaptosomes. Being more like the vivo con­
dition than a more purified preparation, synaptosomes have 
also been claimed to offer greater insight into the 
physiological functioning of these enzyme systems. Notable 
attributes of such preparations include stereoselectivity.
TABLE 1.1
Substrate Specificity of Mammalian Hydroxylating Enzymes*




Noradrenergic cell of brain 
(Tyrosine Hydroxylase)
+ - +
Serotonergic cell of brain 
(Tryptophan Hydroxylase)
- + -




low substrate values, nearly neutral pH optima, inhibition 
by low concentrations of "extracellular" catechols in the 
case of TH (vide infra), and loss of activity following 
selective destruction of the associated nerve endings.
Citing these attributes, Davis (37) recently used synapto­
somal preparations to examine the affinity of tyrosine 
hydroxylase for oxygen.
However, hydroxylation by synaptosomes is a very com­
plex process. It necessitates uptake of tyrosine or trypto­
phan and oxygen into the subcellular particles before the 
enzymatic hydroxylation can occur. The measured enzyme 
activity is, thus, generally limited in such preparations.
To avoid these problems and to obtain higher absolute 
activities, most investigators employ a hypotonic homogenizing 
medium. Such hypotonic solutions lead to extensive lysis 
of cellular and subcellular membranes. Thus, the enzyme 
becomes completely exposed to the homogenizing medium.
Whether one chose hypotonic or isotonic homogenization, 
the preparation of tyrosine or tryptophan hydroxylase, es­
pecially from brain regions, has been historically difficult. 
Even the best preparations cannot presumably avoid eliciting 
alteration in the relevant physical and kinetic properties 
of these enzymes (38). The chemical composition of the sur­
rounding solution is certainly modified in going from the 
in vivo to the homogenized condition. Important regulatory 
factors may also be present in the tissue milieu. Thus,
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many workers prefer the use of crude tissue homogenates 
as the enzyme source to minimize the effects of such altera­
tions from the iji vivo state.
D. Regulation and Control of Tyrosine and Tryptophan 
Hydroxylase. A detailed understanding of the functional 
utilization of catecholamines and indoleamines quite 
naturally focuses upon the enzymes representing the rate 
limiting step in their biosynthesis. The current under­
standing of the regulation of these processes is known to 
involve the following important factors:
1. Availability of substrate and cofactors.
2. Presence of product (for TH) or feedback inhibition,
3. Conformational changes in the protein.
4. Synthesis or degradation of enzyme molecules.
5. Possible existence of endogenous inhibitors and 
activators.
Manipulation of these regulating factors by pharmacological 
or other means will certainly play a major role in correcting 
any associated defects occurring via their possible im­
balance in diseased states.
The simplest method for intervening in these regula­
tory processes is to incorporate an exogenous inhibitor 
into the system. Thus, a great deal of attention has been 
paid to possible inhibitors of both TH and TPH.
Two major groups of inhibitors have been identified
12
for TH (26): tyrosine analogs and catechol-containing
compounds. The latter group is represented by dopa, NE,
DA and 3,4-dihydroxyphenylpropylacetamide (H22/54) (27).
Inhibition by these compounds is known to be competitive 
with the reduced pterin cofactor and uncompetitive with 
tyrosine (26,28). Such inhibition, while typically in­
volving values on the order of only lO”  ̂M, do provide 
an effective product inhibition at the high levels of 
transmitters found within the nerve varicosities.
The tyrosine analogs are much more potent inhibitors 
of TH (26). Those showing the greatest inhibition of TH 
typically have an a-methyl or 3-halogen substituent. Both 
of these groups of compounds exhibit competitive inhibition 
with the substrate tyrosine (26). Included in the latter 
group are 3-iodotyrosine and 3,5-diiodotyrosine, two species 
which are endogenous precursors of thyroxine in the thyroid 
gland. The former group is best represented by a-methyl-p- 
tyrosine. This species has been used to lower the catechol­
amine levels in guinea pigs (23) and other animals to less 
than 1% of control values. This leads to the noticeable 
impairment of motor activity and mild sedation. a-Methyl- 
p-tyrosine has also been used to measure turnover rates 
for catecholamines (24). One simply measures the rate of 
decline of the catecholamine levels following the injection 
of this blocking agent (24). Finally, this agent has also 
seen some limited clinical use in the treatment of hyper-
13
tension (25).
In an attempt to find comparable inhibitors for 
tryptophan hydroxylase, McGeer and Peters (30) screened 
some 700 compounds. They notably added 6-halotryptophans 
and a-methyldopa to the previously known inhibitors, the 4- 
halophenylalanines (29).
A better understanding and associated manipulations 
of these hydroxylating enzymes will certainly necessitate 
employment of highly selective procedures for their deter­
minations. Advances in microdissection techniques (31-34) 
already can provide reproducible tissue samples in the 
vg range. Thus, we have attempted to apply the highly 
selective method of liquid chromatography with electro­
chemical detection to the measurement of these enzymatic 
activities (vide infra).
E. Analytical Procedures. Existing techniques for the 
determination of TH activities are all based upon the con­
version of L-tyrosine to L-dopa. These methods include 
measurement of the dopa produced by spectrophotometry (5), 
fluorometry following intracyclization of dopa according 
to the trihydroxyindole procedure (40-44), various radio­
chemical procedures (45-48), and liquid chromatography 
with electrochemical detection (LC/EC) (49). Since TH 
activity is very low in most cases, only the radioassays 
and LC/EC can routinely provide adequate detection limits
14
and selectivity.
One popular radioassay involves the use of L-tyrosine-
3 33,5- H (45). This is converted to L-dopa-5- H during the
hydroxylation reaction with the release of tritiated water. 
The tritiated water is separated from the rest of the radio­
active materials by cation exchange chromatography and sub­
sequently measured by liquid scintillation counting. A
second radioassay procedure (6) makes use of the conversion
14 14 14of L-tyrosine- C to L-dopa- C. The L-dopa- C is isolated
by adsorption onto an alumina column and then determined by 
liquid scintillation counting.
In the method of Waymire and coworkers (47), L- 
tyrosine-l-^^C is converted to L-dopa-l-^^C. Dopa decarboxy­
lase, which has been added to the incubation mixture then 
leads directly to the formation of dopamine and (gas).
The latter is trapped in a separate vial containing a highly 
basic solution and then subjected to liquid scintillation 
counting. A modification of this procedure has been applied 
to the measurement of labelled DA resulting from the use of 
a substrate which is not labelled on the carboxyl group; 
the DA is isolated by extraction into 3-heptanone after 
complexation with sodium tetraphenylboron (48).
The determination of tyrosine hydroxylase activity 
has also been reported (49) using liquid chromatography 
with electrochemical detection. This report, however, was 
somewhat limited in scope. It employed a less efficient
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column, packed with relatively large particles, rather than 
the highly efficient microparticulate column reported here.
It also focused on the synaptosomal preparation rather 
than hypotonically homogenized samples. This restricted 
its detection limit considerably by yielding lower activities 
when expressed on a per gram basis.
Assay techniques for tryptophan hydroxylase (TPH) 
are generally based upon the conversion of L-tryptophan to 
L-5-hydroxytryptophan (5-HTP). Several of the methods 
reported employ fluorometric detection of the product. In 
these methods, the condensation product of 5-hydroxytryptophan 
with o-phthalaldehyde is measured (51). Radiometric assays 
are more commonly used for TPH due to their higher sensi­
tivity and greater selectivity. Of these, the tritium- 
release procedure (52) seems to be the most frequently em­
ployed. In this method, L-tryptophan-5-^H is enzymatically
3converted to 5-hydroxytryptophan-4- H. Tritium in the 
4-position of 5-hydroxytryptophan, however, exchanges readily 
with water under acidic conditions. The resulting product 
is, thus, acidified and the tritiated water separated from 
the substrate by ion exchange chromatography. Quantitation 
is, again, achieved with liquid scintillation counting.
In the method of Renson (53) the same starting material is 
used, but the product 5-hydroxytryptophan-4-^H is directly 
separated from substrate by ion exchange chromatography and 
measured without acid treatment.
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Ichiyama et al. (54) reported the use of L-tryptophan-
141- C as a substrate for tryptophan hydroxylase. The pro-
14duct 5-hydroxytryptophan-l- C is further converted to 5-HT 
14and COg by added aromatic amino acid decarboxylase. The 
14gaseous COg is trapped in a basic solution and subsequently 
quantitated. Tryptophan hydroxylase activity can also be 
measured through the multiple enzyme procedure of Kizer 
et al. (56). 5-Hydroxytryptophan, the immediate product 
of hydroxylation of tryptophan is enzymatically converted 
to 5-hydroxytryptamine by added aromatic amino acid decarboxy­
lase. This is then converted to N-acetylserotonin by serotonin- 
N-acetyltransferase. Finally, a radioisotope label is 
introduced by the enzymatic méthylation of N-acetylserotonin 
in the presence of ^H-methyl-S-adenosylmethionine and
3hydroxyindole-O-methyltransferase (HIOMT). The H-melatonin 
thus formed is isolated by solvent extraction and counted.
In addition to these radiometric assays, there is 
a method reported for TPH using liquid chromatography with 
fluorescence detection (57). Experiencing considerable 
noise levels, this procedure does not, unfortunately, possess 
a sensitivity comparable to the radiochemical procedures.
Besides the vitro procedures for TH and TPH re­
ported above, there have been many investigations concerned 
with the ^  vivo measurement of activities for these 
enzymes. These procedures, pioneered by Carlsson et al.
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(58,59) measure the buildup of dopa and/or 5-hydroxy- 
tryptophan after ^  vivo blockade of aromatic amino acid 
decarboxylase. Since the endogenous levels of these com­
pounds are very low, measurement of their levels at a 
specific time after injection of the blocking agent yields 
a direct determination of the rate of their formation.
Assuming the existence of a steady state (1) for 
the associated transmitters (rate of synthesis = rate of 
degradation), these measurements also directly indicate the 
utilization, or so-called turnover, rate of these amines.
The initially developed method for in vitro TH described 
in this thesis was, thus, also modified to allow determina­
tions of ^  vivo activities.
II. 5-Hydroxytryptamine (5-HT, Serotonin)
A. General Background. Serotonin was first iden­
tified in biological materials when it was discovered to 
be the factor in serum which stimulated smooth muscle (69, 
70). Since this discovery, it has been shown to be widely 
distributed in nature. In man, the highest concentrations 
occur in the pineal gland, the gastrointestinal tract, and 
the brain. Serotonin is not homogeneously distributed in 
the brain. The highest levels of this transmitter are 
found in hypothalamus, brain stem, neostriatum, and specific 
areas of the limbic system (71-73).
Investigations of the regional localization of
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serotonin in the central nervous system have been greatly 
aided by histochemical techniques. These procedures have 
been used to identify serotonin-containing cell bodies in 
the raphe nuclei of the midbrain, pons and medulla (74). 
Serotonergic nerve terminals have been identified in hypo­
thalamus, the limbic system, and other forebrain and brain 
stem structures (75).
As previously indicated, serotonin is synthesized 
from tryptophan by enzymatic hydroxylation and decarboxyla­
tion in order. The principal route of serotinin degradation 
involves oxidation by monoamine oxidase to the aldehyde. 
Further oxidation to 5-hydroxyindole-3-acetic acid (S-HIAA) 
by aldehyde dehydrogenase or reduction to the alcohol by 
aldehyde reductase is eventually followed by urinary 
excretion.
The role of serotonin as a neurotransmitter has been 
well established. It has also been found to be related to 
certain physiological aspects such as blood pressure (76), 
temperature control (77), and sleep (78). Defects in the 
function and metabolism of serotonin have been postulated 
to be intimately involved in the affective disorders, mania 
and depression (79-81).
In order to thoroughly examine the function and 
regulatory mechanisms associated with this transmitter, 
precise quantitation of serotonin levels and changes in 
its metabolism will have to be accomplished in vanishingly
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small samples. This will encompass highly reproducible 
microdissection techniques as well as assay procedures 
with great selectivity and low detection limits.
B. Analytical Determination. There are many analytical 
techniques currently employed for the determination of 
serotonin. Among these, the fluorometric procedures have 
experienced the most widespread utilization. These pro­
cedures have used native fluorescence in strong acid (82) 
or, for enhanced sensitivity, prior derivatization with
o-phthalaldehyde (83) or ninhydrin (84) . The sensitivity 
obtained by fluorescence methodology, however, is not 
typically adequate for small (yg) tissue samples. Addi­
tionally, the selectivity of these procedures is highly 
questionable when applied to tissues containing compounds 
structurally similar to 5-HT. A recently reported deter­
mination of 5-HT using liquid chromatography with fluoro­
metric detection may alleviate some of these specificity 
problems (88). This method also has a detection limit of 
1 pmol for serotonin.
Gas chromatography-mass spectrometric (GC-MS) (85) 
and radio-enzymatic procedures (86,87) can provide deter­
minations of serotonin in the 0.3-0.5 pmol range. The 
GC-MS procedures, while being virtually specific, require 
chemical derivatization of 5-HT prior to analysis. These 
procedures also necessitate the use of very expensive
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instrumentation leading to a large cost per sample. Radio- 
enzymatic methods for serotonin typically incorporate two 
separate enzymatic conversions. The enzymes involved, un­
fortunately, are not totally specific and the final, labelled 
product is isolated through a nonspecific solvent/solvent 
extraction. Thus, these methods may also suffer a loss in 
specificity due to the presence of other 5-HT related com­
pounds in the tissue samples.
Since the initial employment of liquid chromatography 
with electrochemical detection (LC/EC) for the determination 
of catecholamines by Adams and coworkers (61,92), this 
technique has been demonstrated to possess a high degree 
of selectivity and very low detection limits. It is also 
quite rapid, relatively inexpensive, and quite easy to use 
on a routine basis. Several papers have appeared during 
recent years exhibiting the applicability of this technique 
to the determination of serotonin (89,90,91,93,94). These 
procedures generally maintain all the advantages listed 
above for the LC/EC determinations of catecholamines. They 
typically provide detection limits of 0.1 pmol (20 pg) 
for 5-HT. However, all these methods incorporate some 
sample clean-up process in addition to protein precipitation. 
This may be either a solvent extraction step or isolation 
and subsequent elution from an ion exchange column. The 
sample processing time would, thus, be considerably 
shortened for routine applications if these intermediate
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steps could be eliminated. The LC/EC procedure reported 
herein provides for greater sample throughput by just such 
an elimination, while retaining almost all the advantages 
of LC/EC.
Ill. Liquid Chromatography with Electrochemical Detection 
Recent advances in liquid chromatography (LC) have 
made this technique a very efficient and powerful tool for 
the separation of structurally similar components. It has 
become increasingly important in the analysis of nonvolatile, 
heat-labile, and biologically active compounds. However, 
its application to very low level (pmol) quantitative work 
had to await the development of highly sensitive detectors. 
Included in the group of these detectors is the electro­
chemical device introduced in 1973 (61). This detector 
is simply a thin-layer carbon paste electrode, placed at 
the outlet of the chromatographic column. The electrode 
is maintained at a fixed, predetermined potential with 
respect to a reference electrode, where it may oxidize 
(or reduce) electroactive compounds passing by its surface.
A conventional, three electrode potentiostat is used to 
control the predetermined, constant potential of the working 
electrode and to measure the limiting current resulting from 
the oxidation (or reduction) under these convective flow 
conditions. As little as a few femtomoles of certain com­
pounds can be detected by this method (62) . Additionally,
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this system has been shown (63) to have a linear dynamic 
range of ca. 10^ to 10^.
The column packing materials originally used for the 
determination using liquid chromatography with electro­
chemical detection were typically the pellicular strong 
cation exchange resin, Zipax SCX, or the anion exchange 
resin, Zipax SAX (61,62,64). These two ion exchange resins 
are fluoropolymer based packings with active -SOy or -NR^ 
functional groups and a particle size of 30-40 ym (65).
The interaction of these packings with solute molecules 
typically involves both dispersion forces and ion exchange 
mechanisms, although they rarely conform to the behavior 
one expects from a classical ion exchange system. Zipax 
ion exchangers are unique in having this fluoropolymer 
backbone. Most others, such as Vydac column packings (65), 
incorporate a polystyrene-divinylbenzene backbone. Com­
pounds with an aromatic character usually interact very 
strongly with the backbone resulting in considerably larger 
capacity factors (k' values) and retention times. The 
desired separation of a particular set of compounds can 
usually be achieved by simple manipulation of appropriate 
chromatographic parameters. These parameters include the 
ionic strength of the mobile phase, the pH of the mobile 
phase, the flow rate of the mobile phase, the length of 
the column, the temperature of the column and the particle 
size of the packing material. The major disadvantage of
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using these packing materials lies in the fact that ion 
exchange chromatography is applicable only to the separation 
of ionic sample components. Neutral molecules of interest 
are not retained and thus appear in the so-called solvent 
peak. Moreover, the relatively large particle size (30-40 
ym) of these packing materials greatly hinders their re­
solving capabilities by yielding rather large values for 
the HETP (height equivalent to a theoretical plate). Large 
HETP values also lower the peak capacity of the system, 
thus severely limiting the number of components which can 
be separated in a single chromatogram. As a result, these 
packing materials are gradually becoming obsolete as the 
more recently introduced microparticulate reverse-phase 
columns have emerged in the market place. These micro­
particulate columns are composed of 5-10 ym silica beads 
with chemically bonded organic groups serving as the active 
component of the stationary phase. The small particle size 
leads to a considerable lowering of the HETP and, thus, a 
better resolving power. The most widely used bonded phases 
are those composed of hydrocarbon moeities such as the 
ethyl, octyl, and octadecyl groups. The octadecyl group 
is most frequently used at the present time. Because the 
eluant is generally more polar than the stationary phase, 
the term reverse-phase chromatography, originally coined 
by Howard and Martin (66) is used to describe this liquid 
chromatographic technique. The versatility of these
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chemically bonded materials is further enhanced by the fact 
that they can be operated in either the normal reverse- 
phase mode or a dynamic ion exchange mode (67). In the 
ion exchange mode, polar lipids bearing various functional 
groups (68) are added to the mobile phase. These lipids 
are typically moderate-to long-chain alkane sulfonic acids 
or quaternary amines. The non-polar portion of these modi­
fiers are strongly attracted to the stationary phase through 
dispersion forces and then provide the column with character­
istics resembling chemically-bound ion exchangers. When 
these modifiers are added to the mobile phase, the technique 
is generally referred to as reverse phase ion pair chroma­
tography or, more simply, soap chromatography. The alkyl 
sulfates or sulfonates increase the capacity factor for 
cations, whereas the tetraalkylaramonium salts do likewise 
for anions. This procedure provides highly efficient 
separation for many ionic species, including the catechol­
amines (39,46,60). The ionic strength of the mobile phase 
plays a role in soap chromatography completely analogous 
to what one would expect from ion exchange chromatography; 
increased ionic strength leads to lower k ' values and 
shortened retention times.
When small amounts (or none) of these modifiers are 
added to the mobile phase, the bound stationary phase can 
still interact with neutral and zwitterionic species 
through hydrophobic or dispersion forces (36). This
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leads to the possibility of using a single column for the 
simultaneous separation of a wide variety of molecular 
species in a single chromatographic run (11). Using 
reverse-phase chromatography in this way, we can easily 
adjust the individual capacity factors, as needed, through 
the adjustment of the following parameters: carbon content,
or coverage, of packing material; chain length of the bonded 
stationary phase; pH of the mobile phase; ionic strength 
of the mobile phase; solvent composition of the mobile phase; 
and the proper selection of an appropriate stationary phase 
modifier.
Considering these recent and widereaching improve­
ments in reverse-phase liquid chromatography as well as the 
low detection limits, wide dynamic range, and great 
selectivity of the electrochemical detector, it is of 
little wonder that the combination of these two units repre­
sents the currently preferred methodology for small, electro­
active molecules from tissue or tissue homogenates.
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CHAPTER 2
DETERMINATION OF TYROSINE HYDROXYLASE ACTIVITY BY 
LIQUID CHROMATOGRAPHY WITH ELECTROCHEMICAL 
DETECTION
I. Assay Procedure for ^  vitro Tyrosine Hydroxylase
Activity
A. Introduction
The need for a rapid and sensitive technique for 
the determination of tyrosine hydroxylase (TH) activity has 
been amply demonstrated (vide infra). This need was par­
tially fulfilled in 1976, when this laboratory introduced 
a procedure (1) employing liquid chromatography with electro­
chemical detection(LC/EC). While offering some distinct 
advantages over competitive methods, this procedure cur­
rently has only a limited applicability. This situation 
is due to a number of instrumental and theoretical advance­
ments that have taken place in the intervening time. The 
present report may, therefore, be considered an extension 
of the previous work with emphasis upon modifications in 
the following specific areas: (1) the use of a micro­
particulate reverse-phase column to achieve better resolu-
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tion, higher sensitivity and shorter analysis times; (2) the 
use of a hypotonic tissue homogenate in the incubation to 
increase the measured activity over the previously employed 
synaptosomal preparations; (3) the use of 6-MPH^ (6-methyl- 
tetrahydropterin) as a cofactor to replace DMPH^ (6,7- 
dimethyl-tetrahydropterin); (4) the reassessment of optimal 
conditions for other experimental parameters, (pH, temperature, 
etc.) obtained after these changes were added to the pro­
cedure; and (5) the careful examination and minimization 
of blank values (noise levels) in order to improve the 
detection limit of the procedure.
B. Development of the Assay Procedure
1. Overview. In vitro TH assays may be conveniently 
divided into the following general steps; (1) incubation 
of the enzyme preparation with the substrate, cofactors, 
a dope decarboxylase inhibitor, and associated chemicals;
(2) isolation of the hydroxylation product, dopa (3,4-di- 
hydroxyphenylalanine), from the incubation mixture; and
(3) separation and quantitation of the dopa formed. The 
development of the present assay procedure quite naturally 
examined each of these steps in reverse order. A method 
for quantitation was required before the isolation procedure 
could be investigated, and both quantitation and isolation 
were required before incubation could be investigated.
After outlining the materials and methods appropriate to
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the entire assay, we will go back and discuss the develop­
ment of each of these steps as they occurred in the present 
investigation.
2. Materials and Methods,
a . Apparatus :
Liquid Chromatography. The liquid chroma­
tograph with an electrochemical detector has been adequately 
discussed in general terms in Chapter 1. For some of the 
initial work, we used a system identical with that described 
by Blank and Pike (1). However, this was quickly discarded 
during an investigation of the chromatographic conditions. 
The present system is composed of the following components:
Pump: Milton Roy Minipump, Model No. 13906-1,
5,000 p.s.i. maximum pressure.
Damping Coil: Li-Chroma-Damp from Hardy & Harman
Tube Co., Norristown, PA, 2,000 p.s.i. 
maximum operating pressure.
Connecting Tubing : Stainless Steel (SS 316) ,
0.009 in i.d.
Injector: Rheodyne Model 7120 Sample Injector.
Detector: Homemade, as previously described (1).
Detector Electronics: The potential controller/
current monitoring instrument was identical 
to that previously described (1).
Column: 4.6x150 mm Ultrasphere ODS, 5 ym particle
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size from Beckman,
Pressure Limiter; Electronic device attached to
pressure gauge to shut off pump when pressure 
>2,000 p.s.i. This unit was constructed by 
Peter Lin in our laboratory to prevent damage 
to the damping coil.
Chromatographic Conditions :
Mobile Phase: A solution containing 0.025 M
citric acid, 0.050 M sodium acetate,
0.060 M NaOH, and 0.019 M acetic acid 
was passed through a 0.4 ym Millipore 
filter prior to use.
Flow Rate: 0.3 ml/min.
Detector Potential: 0.65 V vs. Ag/AgCl.
Tissue Homogenizer: A Potter-Elvehjem glass/Teflon
homogenizer from Kontes Glass was used. The 
Teflon pestle was driven by a Fisher model 43 
Dynamix motor, connected via a piece of rubber 
tubing.
Centrifuge; Sorvall RC2-B refrigerated, high-speed 
centrifuge equipped with an SM-24 rotor. 
Shaker: An Eberbach, Model No. 6010 shaker was
operated at either 280 cycle/min or 180 
cycle/min.
Vortex Mixer: VORTEX-GENIE, Scientific Industries,
Inc., Springfield, MA.
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Incubator; Sherer, Controlled Environment Chamber, 
Model CEL 37-14.
b. Animals:
Adult male mice, typically 6-12 weeks old, 
of the Sprague-Dawley ARS-HA/ICR (albino) strain were ob­
tained from Gibson Laboratories of Madison, WI. The animals 
were maintained on a 12 hr. light/12 hr. dark cycle (lights 
on from 6 a.m. to 6 p.m.) and allowed access to food and 
water ^  libitum. No mice were used in any experiments 
until they had been allowed one week to become accustomed 
to the local conditions. In the typical assay, the animals 
were sacrificed between 10 and 12 a.m. by cervical dislocation.
c. Reagent Sources:
3.4-Dihydroxyphenylalanine (dopa)- 
Aldrich Chemical Co., Milwaukee, WI.
Dopamine hydrochloride (DA»HC1)-Aldrich.






6-Methyl-5,6,7,8-tetrahydropterin (6-MPH^) - 
Sigma Chemical Co., St. Louis, MO.
NSD-1034 IN'-Methyl-N'-(3-hydroxybenzyl) 
hydrazinium dihydrogen phosphate] -
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Sandev Research, Gilston Park, Hartlow, 
England.




All other chemicals were purchased from commercially 
available sources in the highest available purity and used 
without further purification. Water used for preparation 
of all solutions was double-distilled.
d. Stock Standard Solutions:
Dopa (500 tjM) - prepared by dissolving 9.84
-3mg dopa in 100 ml of a 1x10 M ascorbic 
acid solution. The resultant solution 
was always used within 2 weeks.
NE/DA (NE-600 yM, DA-800 yM) - prepared by 
dissolving 14.98 mg NE*HC1 and 19.33 mg 
DA'HCl in 100 ml of 10 ^ M ascorbic acid. 
The resultant solution was never kept 
over 2 weeks. '
e. Working Standard Solution:
On the day of use, a 1.00 ml aliquot of the 
dopa stock standard and a 1.00 ml aliquot 
of the NE/DA stock standard were transferred 
to a 100 ml volumetric flask and diluted 
to the mark with a 1x10 ^ M ascorbic acid 
solution.
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f. Internal Standard Solution;
-4A solution of 8x10 M DHBA was prepared by 
dissolving 17.6 mg of DHBA'HBr in 100 ml of 
1x10 ^ M ascorbic acid solution. On the day 
of use, a 1:10 dilution of this solution 
is made with a 1x10  ̂M ascorbic acid 
solution.
g. Blank solution:
On the day of analysis, a 1.00 ml aliquot 
of the NE/DA stock solution was diluted to 
100 ml with the 10 ^ M ascorbic acid 
solution.
h. Ascorbic Acid Solution:
Prepared immediately before use, the IxlO”^
M ascorbic acid solution was obtained by 
dissolving 40 mg of ascorbic acid in 250 ml 
of distilled water.
i. Acid washed alumina was prepared as described 
by Anton and Sayre (2).
j. Alumina Wash Solution:
Contained 100 nl of 0.1 M EDTA, 100 yl of 
1 M NaHSOg, and 1 ml of Tris buffer, (0.5 M, 
pH 8.60) per 100 ml of distilled water, 
k. Dopa Elution Solvent:
On the day of analysis, 50 ml of 0.03 M 
HCIO^ containing 0.025 M KCIO^ was deaerated
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for 15 minutes. 20 yl of a 1 M NaHSOg 
was added, and the solution was thoroughly 
mixed.
1. The Standard TH Assay Procedure;
The procedure was started by sacrificing the 
animals. The brains were removed as quickly as possible, 
weighed and stored on ice. Homogenization, effected with 
the glass/Teflon homogenizer, incorporated the following 
materials in the listed proportions:
1 brain/2.00 ml H2O/200 yl DHBA internal standard 
solution
The incubation mixture was prepared by mixing the 
following components to yield a total volume of 500 yl.
The concentrations of the components in the final mixture 
are given in parentheses: 100 yl of a 1.0 M acetate buffer,
(0.20 M) containing 0.05 M phosphate (0.01 M) and having a 
pH of 6.1; 50 yl of a solution which is 4.0 mM in DMPH^
(0.4 mM), 2.0 M in 2-mercaptoethanol (0.2 M ) , and 4.0 mM 
in benzyloxyamine (0.4 mM); 50 yl of a 10 mM ferrous sulfate 
solution (1.0 mM) containing 10.0 unit/yl (1.0 unit/;jl) 
catalase; 50 yl of 1.0 M L-tyrosine (0.10 mM) in 0.010 M 
HCl (0.001 M); and, 250 yl of the brain homogenate. All 
these solutions, except the L-tyrosine and the brain homo­
genate were preincubated after mixing at 37®C for 30 minutes. 
The calculation of the final concentrations of the individual 
components in the incubation mixture, incidentally, assume
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the homogenate is an aqueous solution with negligible amounts 
of particulate matter.
Standard 'homogenates', containing a known concentra­
tion of dopa, were prepared by mixing 500 yl of the dopa 
working standard with 2.00 ml of distilled water and 200 yl 
of the DHBA internal standard solution. 250 yl of this 
solution replaced the brain homogenate in the above pro­
cedure to provide a standard incubation mixture.
Since tyrosine solutions contain dopa as an impurity 
and dopa is produced by nonenzymatic routes from tyrosine
(5), it is important to run blanks for each assay. This 
is accomplished by replacing the brain homogenate in the 
incubation mixture with 250 yl of a solution prepared by 
mixing the following components: 500 yl NE/DA blank
solution, 2.00 ml HgO, and 200 yl of the DHBA internal 
standard.
The incubation mixture was placed in a capped centri­
fuge tube, and the incubation was carried out at 37®C in an 
air bath for 30 minutes. The tubes were positioned hori­
zontally in the shaker with the long axis parallel to 
the direction of shaking. The shaker was set on the high 
speed setting. The reaction was terminated with the addition 
of 200 yl of 1 M HCIO^. 50 yl of a solution containing 0.30 
M NaHSO, and 0.030 M EDTA was also added to inhibit oxidation 
of the catechols. The samples were then centrifuged at 
16,000xg and 4®C for 15 minutes with storage on ice before
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and after.
500 pi of the supernatant was placed in a small vial 
containing 20 mg of acid-washed alumina and 2.00 ml of a 
0.50 M Tris buffer at pH 8.50. The buffer was previously 
deaerated for 15 minutes with Og-scrubbed Ng (6). The 
vials were shaken at room temperature for 15 minutes. Upon 
removal from the shaker, the alumina was allowed to settle.
The supernatant solution was removed with a Pasteur pipette 
connected to a vacuum aspirator. The alumina was washed 
three times (shaking for 3-5 seconds on a vortex mixer, 
settling, and aspiration) with 2.00 ml of deaerated wash 
solution. The compounds of interest were eluted from the 
alumina by addition of 200 pi of elution solvent. The vials 
were thoroughly mixed (3-5 seconds) by use of a vortex mixer 
to insure homogeneity.
About 5 pi of the alumina solvent was finally injected 
into the LC/EC for the separation and quantitation of dopa, 
m. Calculations:
The amount of dopa formed by the hydroxy­
lation reaction per unit time per unit weight is a direct 
measure of the TH activity. The calculation of this activity, 
thus, incorporated the ratio (R) of peak heights for dopa 
and DHBA for the sample, the standards, and the blanks. A 
typical calculation is given as:
Dopa formed (nmol/g/hr) =
R —R[■ sample blank, .nmol dopa in a standard incubation mixture, 
Rg^^-R^2^nk (tissue, wt, g) (incubation time, hr)
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The and Rj^^ank values represent the average ratios for
ail standards and blanks run during a particular analysis.
Each result in this chapter, which is expressed with an 
estimate of uncertainty represents the mean ± the standard 
error of the mean (S.E.M.) for at least four separate deter­
minations. Each experiment was also typically repeated 
to confirm its validity. Statistical comparisons of data 
sets were performed with the Null Hypothesis using Student's 
t-distribution (7).
3. Chromatographic Conditions
The LC/EC procedure previously developed for 
the TH assay employed a column with very low resolution.
This column also provided separations rather exclusively 
for cations. Consequently, a mobile phase with a very low 
pH had to be employed to convert the zwitterionic amino 
acid, dopa, into its positively charged form. Unfortunately, 
under these conditions small amounts of ferrous ion suddenly
become visible in the chromatogram. The source of this
+2 +2 Fe is not presently known. And, although Fe is well
separated from the other compounds of interest, its relatively 
large retention time significantly increases the time re­
quired for each analysis (see Figure 2.1). Unsuccessful 
attempts were made to solve this problem by adding complexing 





02 0  min
Figure 2.1 Low Resolution Chromatogram Used in Previous 
TH Assay.
Column: Zipax SCX, 750x3 mm
Mobile Phase: 0.025 M KCIO4, 0.030 M HCIO4
Flow Rate: 0.7 ml/min
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phase and by adjusting the pH of the mobile phase (3).
+2At a pH > 4, however, Fe no longer appears in the chromato­
grams. But, dopa is not retained at this pH.
We, thus, clearly welcomed the recent commercial 
availability of microparticulate reverse-phase columns. 
Operated in the normal reverse-phase mode, the pH of the 
mobile phase can be significantly raised for these columns 
without eliminating the retention of dopa. After trying 
several mobile phases, including different molarities and 
pH values for citrate/phosphate and citrate/acetate buffers, 
we found that the citrate/acetate buffer, described in the 
Materials and Methods section of this chapter, provided the
desired separation for all the compounds involved in the TH
+2assay (see Figure 2.2). The elimination of the Fe inter­
ference, coupled with the high efficiency of the micro­
particulate column, effectively cut the analysis time in 
half. It should be noted that the LC/EC must adequately 
separate norepinephrine (NE), dopamine (DA), 3,4-dihydroxy- 
phenylacetic acid (DOPAC) and 3,4-dihydroxybenzylamine 
(DHBA) in addition to dopa. NE, DA and DOPAC are endogenous 
components of brain, while DHBA is the added internal stan­
dard. And, all four of these species will be isolated from 
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Figure 2.2 High Resolution Chromatogram Used in Current 
TH Assay
Column ; Ultrasphere ODS, 150x4.6 mm 
Mobile Phase; Citrate/acetate, pH 5.1 
Flow Rate: 0.3 ml/min
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4. Isolation Procedure
The isolation of dopa from the incubation mixture 
is most efficiently accomplished by the alumina adsorption 
procedure of Antone and Sayre (2). This is a highly pH 
dependent process, with selective adsorption onto AlgOg 
being obtained for compounds containing a catechol moiety 
at pH 8.6. After washing the AlgO^-bound species, their 
elution is achieved by simply lowering the pH of the con­
tacting solvent.
Being concerned about the applicability of this AlgOg 
isolation procedure to the present incubation mixtures, we 
decided to accurately determine the efficiency of the pro­
cess in the presence and absence of tissue homogenates.
This study incorporated incubation mixtures with brain 
homogenates (samples) and incubation mixtures without brain 
homogenates (blanks). Varying amounts of dopa solutions 
and fixed amounts of DHBA were added to these mixtures.
Some of the standard dopa and DHBA solutions were subjected 
to LC/EC quantitation at this point. The remaining samples 
and blanks were then carried through the alumina adsorption 
procedure. After elution from alumina, a precisely measured 
amount of the eluate was injected into the LC/EC system.
The observed peak heights for both DHBA and dopa, after cor­
recting for dilution, were compared with those from the 
original standard solutions to obtain the percent recovery 
for each species. Typical results are listed in Table 2.1.
TABLE 2.1
Percentage Recovery of Dopa and DHBA After Alumina Adsorption
Compounds Percentage Recovery





The linearity of the peak height ratio of dopa and 
DHBA ^^^Dopa^^DHBA^ VS. the amount of dopa added during the 
adsorption process was also obtained from these studies.
The results for the samples containing tissue homogenates 
are shown in Figure 2.3. As can be seen, excellent 
linearity is obtained for the usual values of dopa encountered 
in routine TH assays.
5. Optimization of Incubation Parameters
The initial incubation conditions are presented 
in the Materials and Methods section of this chapter. These 
conditions represent a carefully selected combination of a 
number of existing TH procedures. But, even a careful 
selection does not necessarily provide optimal conditions. 
Thus, we decided to optimize these incubation parameters. 
Appropriate ranges of each parameter were examined while 
holding all others constant. On occasion, appropriate 
ranges of alternate reagents were also examined. The 
sequence of the parameters investigated, however, is impor­
tant. The optimum for a given parameter, once determined, 
was incorporated into the procedure for all subsequent 
optimization studies. It should also be noted that all con­
centrations refer to the final incubation mixture.
a. Molarity of Acetate Buffer. The concentra­
tion of the buffer system used in enzymatic assays fre­
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Figure 2.3
Dopa ( nmol )
Relationship Between the Peak Height Ratio of 
Dopa and DHBA and the Amount of Dopa Added 
in the Alumina Adsorption Procedure.
The amount of dopa added was varied between 
0,014 nmol and 0.56 nmol. The amount of DHBA 
was fixed at 0.98 nmol.
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TABLE 2.2
The Effect of Concentration of Acetate Buffer on
TH Activity








the investigation of the molarity of the acetate buffer in 
the TH assay are presented in Table 2.2 As can be seen, 
the TH activity reached a reasonably high value at a buffer 
concentration of 0.20 M. While the higher concentration,
0.50 M, yielded a slightly higher activity, it is incon­
venient to employ in routine investigations. Its concen­
trated form often provides solid formation upon slight 
evaporation. This solid material leads to pipet clogging 
and associated difficulties. Thus, the 0.20 M buffer was 
used for all subsequent determinations.
b. pH of Acetate Buffer. Previous studies 
have indicated that TH activity is highly pH dependent.
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Figure 2.4 The Effect of Buffer pH on TH Activity.
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occurs at a pH of 6.4. This value is a bit higher than the 
value of 6.0 previously used by a number of workers (8,9).
The multiple differences (enzyme source, animal species, 
incubation parameters, etc.) between the current and previous 
investigations, however, preclude a direct assessment of 
this apparent pH shift. All the following studies used a 
pH of 6.4.
c. Phosphate Concentration. Some reports of 
TH assay procedures (8) have claimed that phosphate, added 
to the incubation mixture, provides greater measured activity 
levels. In the present system, as indicated in Figure 2.5, 
the addition of phosphate caused a decrease in the measured 
activity, with higher concentrations eliciting lower 
activities. Therefore, phosphate was eliminated from sub­
sequent determinations.
d. Catalase. Catalase has been reported by 
some to enhance TH activity. The results of the present 
investigation, however, do not support these reports (see 
Table 2.3). The smallest concentration (0.01 unit/pl) 
tested appears to provide a minimal increase in activity.
But, this result is not significantly different from the 
case where no catalase was added. Thus, catalase was 
omitted from all subsequent assays.
e. Ferrous Ion. As indicated in Chapter 1, 
the role of the ferrous ion in TH assays is still somewhat 
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The Effect of Catalase on TH Activity








*1 unit of catalase decomposed 1 ymol of H2O2 per minute at 
pH 7.0 and 25°C while the H2O2 concentration in the reaction 
mixture falls from 10.3 to 9.2 mol per ml. The solid 
material used as the source of catalase in this experiment 
exhibited 3,000 units/mg.
**Not significantly different from the result for 0 unit/yl 
(P>0.05).
TABLE 2.4
The Effect of Iron(II) on TH Activity
+2Fe Concentration 
(mM) ^lank








+2of the effect of Fe are listed in Table 2.4. These results 
clearly demonstrate that the ferrous ion has a significant 
effect on TH activity in the present procedure. It has also 
been reported, however, that the ferrous ion contributes 
to the nonenzymatic hydroxylation process (25). Thus, 
blanks were simultaneously run for each of the investigated 
values of Fe*^ concentration. The choice of an "optimal" 
value under these conditions can be appropriately interpreted 
in two distinct ways. One optimum would simply be that 
which yields the greatest measured TH activity. An alterna­
tive optimum is that which yields the highest ratio of
tissue/blank values. Both of these viewpoints were con-
+2sidered in selecting 0.10 M Fe as the overall optimum 
value. While yielding the maximum measured activity, 
however, it should be noted that this concentration does
not represent the maximum signal/noise ratio. The maximum
+2 +2 ratio occurs with no added Fe . Nonetheless, 0.10 M Fe
was employed in all subsequent assays.
f. Dopa Decarboxylase Inhibitors. The previous
assay for TH originating from this laboratory had selected
benzyloxyamine (BOA) as the dopa decarboxylase inhibitor
primarily due to its commercial availability (1). However,
this agent exhibited some noticeable inhibitory properties.
Thus, we decided to include NSD-1015 and NSD-1034 in the
present investigation. As shown in Figure 2.6, none of
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Figure 2.6 The Effect of Different Dopa Decarboxylase Inhibitors on TH Activity.
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at higher concentrations. Based upon the results, however,
0.04 0 M NSD-1015 was selected as the optimal value for the 
following assays.
g. Pterin Cofactor, The effect of two different 
cofactors, DMPH^ and 6-MPH^, on the rate of formation of 
dopa were also investigated. The results are presented
in Tables 2.5 and 2.6. The two data sets are not strictly 
comparable since each cofactor investigation was run on a 
separate day and employed different brain homogenates. 
Nonetheless, some general comments are appropriate.
Both of the cofactors tested have a significant effect 
on the production of dopa, and 6-MPH^ appears to be slightly 
more effective. A concentration of 1.5-2.25 mM was re­
quired for 6-MPH^ to provide an approximately maximal 
activity, while 4.0 mM was required for DMPH^. This is in 
agreement with a previous report (12) that 6-MPH^ is approxi­
mately twice as efficient as DMPH^ in its role as cofactor.
A kinetic analysis of the data for 6-MPH^ is shown 
in Figure 2.7. The double reciprocal plot in this figure
was used to determine the K (0.31 mM) and (97.6 nmol/m — max
g/hr) values for this cofactor. Subsequent assays employed 
2.0 6-MPH^.
h. 2-Mercaptoethanol. This compound is fre­
quently employed in enzyme assays as a protein activator (11). 
It can also serve as a reducing agent to inhibit the non- 
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The Effect of 6-MPH^ on TH Activity











of 2-mercaptoethanol in the present assay, as seen in Figure
2.8, appears to both stimulate and inhibit TH activity. The 
optimal value of 0.050 M was selected for subsequent assays.
i. Incubation Temperature. Previous studies 
of TH have fairly uniformly employed 37“C as the incubation 
temperature. We briefly examined the applicability of this 
temperature by comparing it to higher (40®C) and lower (34®C) 
values. As seen in Table 2.7, 37®C does, indeed, yield the 
optimal TH activity.
j. Shaking Parameters. These parameters include 
the shaking rate during incubation and orientation of the 
centrifuge tubes containing the incubation mixtures. The 
results are listed in Table 2.8. For these studies, it 
should be noted, the direction of shaking was horizontal. 
Also, a horizontal tube position means the tube was not 
only laying on its side, but the long axis of the tube was 
parallel to the direction of shaking.
As expected, the horizontal tube placement yields 
the maximal TH activities with no significant differences 
being observed for the two shaking rates. At either shaking 
rate, the vertical placement results were not effected by 
having the tubes capped or uncapped. But, the faster shaking 
rate provided smaller activities with vertical placement.
This result cannot be completely explained at the present 
time.
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Figure 2.8 The Effect of 2-Mercaptoethanol on TH Activity,
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TABLE 2.7
The Effect of Incubation Temperature on TH Activity 







♦significantly lower than the result obtained at 37“C (P<0.05)
TABLE 2.8
The Effect of Shaking Rate and Position of Incubation 
Tube on the Rate of Dopa Production


















the maximal TH activity. But, handling for this placement
requires capping prior to incubation and uncapping after
incubation for each sample. The uncapped vertical placement
at a slow shaking rate, on the other hand, does not necessi-■
tate such inconveniences and yet yields an activity that
is not significantly different from the horizontal placement.
For this reason, the uncapped vertical conditions and the slow
shaker rate were selected as optimal for routine application.
k. Tyrosine. The concentration of tyrosine
contributes to both the enzymatic and nonenzymatic formation
+2of dopa. As in the investigation of Fe , therefore, an 
optimal value must consider both of these processes. Practi­
cally, one must select the minimal saturating value for 
tyrosine. The effects of varying substrate concentration 
on both tissue samples and blanks are presented in Table
2.9. The Michaelis-Menton kinetic plot of this data is 
shown in Figure 2.9. The tyrosine values used to construct 
Figure 2.9, it should be noted, incorporated the endogenous
tissue value of 10 yg/g for the substrate (13). From this
-5data, the derived values of and are 4,0x10 M  and
131 nmol/g/hr, respectively. Thus, the minimal saturating 
value of 0.25 mM was selected for all the following assays.
1. Incubation Time. As shown in Figure 2.10, 
linear accumulation of dopa ceases after an incubation 
time of approximately 20 minutes. Thus, all subsequent 
determinations employed a 20 minute incubation period.
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The Effect of L-tyrosine on the Rate of Dopa Formation.
The contribution of endogenous tyrosine from the tissue homogenate 








Figure 2.10 The Effect of Incubation Time on TH Activity.
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TABLE 2.9










m. Preincubation Time. Regardless of the 
source of enzyme, preincubation of some of the incubation 
components has been shown to provide greater activities. 
However, results for hypotonically homogenized whole mouse 
brain samples have not been previously reported. Thus, we 
decided to examine the need for preincubation in the 
current procedure. One group of samples was preincubated 
for 30 minutes before the addition of substrate and tissue 
homogenate while another group was processed without any 
preincubation. As expected, the group which had been pre­
incubated provided higher activities (115±14 vs. 91+12 
nmol/g/hr). Therefore, preincubation was retained in 
the present procedure.
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n. Enzyme Concentration. Finally, the obser­
vation of TH activity as a function of the amount of added 
enzyme (expressed as the volume of added brain homogenate) 
was undertaken to ascertain the absence of any endogenous 
inhibiting materials in the homogenate. The results for 
this investigation are shown in Figure 2.11. As can be 
segn, the amount of dopa formed was linearly dependent on 
the amount of homogenate added to the incubation mixture.
Thus, the originally selected amount of tissue homogenate 
experiences no inhibition from endogenous factors and is 
completely appropriate for routine analysis.
6. Minimizing Blank (Noise) Levels.
Blank values directly affect the limit of
detection for TH assays. The signal to noise ratio obtained
by these determinations may be conveniently expressed as
the tissue/blank level. Thus, attempts to lower the detection
limit are naturally concerned with minimizing the blank
values. A major contribution to blank values is presumed
to arise from nonenzymatic hydroxylation of the substrate.
This reaction has been extensively studied for the related 
+2Fe /Og/tetrahydropterin/phenylalanine system (25), where 


















f r a g m e n t a t i o n
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Due to the structural similarities between tyrosine and
phenylalanine, it is assumed that nonenzymatic formation
of dopa from tyrosine proceeds through a similar mechanism.
From this mechanism, it is apparent that the concentrations
+2of both tyrosine and Fe would directly affect the unde­
sirable production of dopa. We, thus, decided to more 
thoroughly examine the importance of these concentrations.
As seen in the upper part of Table 2.10, nonenzymatic dopa
+2production clearly increases with increasing Fe concen-
+2trations. At 10 mM Fe , no dopa was obtained from the
AlgOg eluate. However, this was later shown to result from
+2the direct adsorption of Fe leading to the loss of ad­
sorption sites for dopa. The third and fifth points in 
the upper part of Table 2.10 additionally demonstrate the 
seemingly greater dependence of nonenzymatic hydroxylation 
upon the tyrosine concentration.
A second likely source of nonenzymatic dopa is re­
presented by the dopa impurity present in the Vpure"
TABLE 2.10
+2The Effect of Fe and Tyrosine on Blank Values
+2Cone. Fe (mM) Incubation/Preincubation 
Times (min)
Cone, Tyrosine (mM) ^blank
0.0 20/30 0.10 0.090+0.005
0.4 20/30 0.10 0.313+0.005
1.0 20/30 0.10 0.440±0.011
10.0 20/30 0.10 __*
1.0 20/30 0.40 1.52+0.04
0.0 0/0 0.4 (purified) 0.044±0.004
0.0 0/0 0.4 (unpuri­
fied)
0.066±0.005
*No dopa is found after AlgOg adsorption. See text.
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tyrosine used as a reagent. Purification of commercial 
tyrosine according to the methods of Nagatsu (5) and Ikeda
(7) was undertaken to investigate this possibility. The 
results of the comparison between this "purified" tyrosine 
and the unpurified, commercially obtained material is shown 
at the bottom of Table 2.10. No incubation or preincubation 
was employed for these samples so as to detect only the 
contribution from impurities. The purified material provided 
blank values only slightly lower than the unpurified mater­
ial. This difference appears even less important when one 
considers the contribution of impurities to the total non­
enzymatic dopa. Thus, purification of tyrosine was deemed 
unwarranted for routine determinations of TH activity. In 
connection with the existence of dopa impurities in com­
mercial tyrosine sources, we should mention that a number 
of authors employing radioassays have promoted the use of 
D-tyrosine for blanks. We would suggest that this may be 
inappropriate. The radiolabelled D-tyrosine used in the 
blank is almost certain to contain a different fraction of 
dopa impurity than is the L-tyrosine used for sample.
The dopa impurities in both the D- and L-sources should 
be carefully examined before they are used interchangeably.
It is also conceivable that NE and DA, normally 
added to blanks, could be inhibiting the nonenzymatic pro­
duction of dopa. This is very reasonable since both of 
these compounds are aromatic and both are relatively
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easily oxidized. The additions of these compounds to blanks 
is completely justified since they are normal components 
of the tissue homogenates. Nonetheless, we decided to 
examine the effect of added NE and DA on blanks just to 
satisfy our curiosity. As seen in Table 2.11, these com­
pounds do, indeed, inhibit the nonenzymatic production of 
dopa.
Our investigations of blanks can be summarized as 
follows:
a. The major contribution to blank values is repre­
sented by the nonenzymatic production of dopa.
This source of dopa is very strongly affected
by the concentration of tyrosine in the incubation
+2mixture. It is also affected by the Fe con­
centration.
b. Dopa impurities in commercially obtained L-tyrosine
TABLE 2.11
The Effect of Added NE and DA on Blank Values




are a second source of dopa found in blanks. 
Although normally representing only a small 
part of the total nonenzymatic dopa, this source 
should be examined if blank values become unex­
pectedly high in routine applications,
c. NE and DA additions to blanks inhibit the non­
enzymatic production of dopa. These substances 
should, thus, always be added to blanks and 
standards at concentrations comparable to that 
contained in the tissue samples.
7. Summary of Results
The final, optimal conditions for the assay 
of vitro TH activity are presented in Table 2.12. The 
optimal assay is simply obtained by replacing the initial 
conditions in the Materials and Methods section of this 
chapter with the optimal values listed in this table.
Employing the optimal conditions, a typical assay 
for ^  vitro TH activity produced a value of 117±4 nmol/g/hr 
for whole mouse brain. Since there is no other data avail­
able in the literature for TH from hypotonically-homogenized 
whole mouse brain, a comparison with values from rat brains 
was undertaken. Cicero et al., for example, reported 
a value of 94.5±4.2 nmol/g/hr for whole rat brain (15), 
while values of 120±4 nmol/g/hr can be calculated from the 
data of Waymire et al. (16). Our values for mouse, thus.
TABLE 2.12 
Summary of Optimization of the TH Assay
Parameter Initial Condition Optimization Range Optimized Values
Cone. acetate 
buffer 



































































demonstrate a reasonable degree of agreement with those 
reported for rat by these workers. The present technique 
was even further validated when we used whole rat brains 
as the enzyme source in our procedure. This yielded a 
TH activity of 100±5 nmol/g/hr, which is completely com­
parable to the previous reports.
As mentioned before, the ultimate detection limit 
for the jji vitro TH procedure is determined by the tissue 
to blank (or signal to noise) ratio. For the present pro­
cedure, this is equivalent to:
^^sample ^blank)/^blank 
The ^  vitro TH procedure with the highest reported tissue
to blank ratio is that of Waymire et al. (16). This pro-
14 14cedure measures CO^ produced from L-tyrosine-1- C after
hydroxylation by TH and subsequent decarboxylation of the 
dopa formed. Since these authors used whole rat brain as 
the enzyme source, we did the same to allow a direct com­
parison. As seen in Table 2.13, both methods provide com­
parable tissue to blank ratios.
But, we believe the LC/EC procedure is and/or should
be better than the radioassay in its ultimate detection
+2limit. The radioassay employed tyrosine and Fe concen­
trations in the incubation mixture which were, respectively, 
smaller and larger than those used in LC/EC procedure 
(0.10 mM vs. 0.25 mM and 1.0 mM vs. 0.10 mM). The effects 
of these differences on blank values should either cancel
TABLE 2.13
Comparison of Sensitivity Between LC/EC and Radioassay













et al. (16) ] 1.0 120±4 51,085 (dpm) 1,412 (dpm)* 36
♦incubation included 2 mM 3-iodotyrosine.
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or slightly favor the LC/EC procedure if eliminated.
More importantly, the radioassay employs blanks that are 
composed of normal tissue samples with added 3-iodotyrosine, 
a TH inhibitor. This causes two sources of possible error 
in these blanks. First, the 3-iodotyrosine is likely to 
inhibit the nonenzymatic production of dopa (compare the 
effect of NE & DA in the present study). Alternatively,
3-iodotyrosine may simply compete with the labelled substrate 
for nonenzymatic hydroxylation. Either case will produce 
an artificially low blank value for this procedure. Like­
wise, these effects will serve to artificially raise the 
observed tissue to blank ratio.
The detection limit of the present assay condition, 
if necessary, may be further decreased by making the fol­
lowing changes to the incubation procedure;
a. Use 'purified' tyrosine.
b. Use the horizontal position for the centrifuge 
tubes.
c. Use a lower concentration of tyrosine.
+2d. Use no added Fe
The last two of these suggestions, unfortunately, will yield 
a lower value of measured TH activity along with an improve­
ment in the tissue to blank ratio. Other factors that 
may be important in this regard are the concentration of
the cofactor (6-MPH^), the concentration of the 2-mercapto-
+2ethanol, and the possible replacement of Fe with catalase.
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The concentration of 6-MPH^ and 2-mercaptoethanol were 
optimized for maximal TH activity in the present investi­
gation, but not for maximum tissue to blank ratios. The
+2catalase, tested in the presence of Fe , was also maxi­
mized only with regard to observed activity.
C. Application of the Developed Procedure for in
vitro Tyrosine Hydroxylase Activity. Determination 
of TH Activity in Mouse Brain Striatum After 
Sacrifice by Microwave Irradiation
1. Background. Rapid post mortem degradation of 
endogenous transmitters and related metabolites has been 
an area of great concern to persons employing neurochemical 
measurements. In an investigation undertaken by this 
laboratory, it was found that dopamine (DA) might be ex­
periencing just such a problem in the striatum (22). How­
ever, the method employed for rapid inactivation, microwave 
irradiation, is only presumed to elicit heat-induced dé­
naturation of the relevant biosynthetic and biodegradative 
enzymes involved. Using the procedure just developed, we 
decided to validate the presumed inactivation for TH. 
Simultaneously, the activities of dopa decarboxylase, mono­
amine oxidase and catechol-O-methyltransferase were 
examined by appropriate procedures.
Excessive heat application through microwave ir­
radiation can lead to both heat related destruction of the 
transmitters and pressure-induced spreading of the tissues
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involved. This latter problem elicits a virtual loss 
of regional integrity. On the other hand, insufficient 
heat will not provide the essential loss of enzymatic 
activity. The present study, thus, examined the loss 
of enzyme activity as a function of the amount of micro­
wave irradiation employed.
2. Procedure. The mice were sacrificed by expo­
sure to microwave irradiation (2450 MHz, 7.5 kW) concen­
trated on the head. This technique has been adequately 
described by Stavinoha et al. (23). The time of irradiation 
varied between 0 and 250 msec, with the animals receiving 
no irradiation being sacrificed by decapitation 
with a guillotine. The brains were removed immediately 
after sacrificing and dissected. The striata were weighed 
and stored on dry ice. Determination of the TH activity 
was performed, typically, within 24 hrs.
The optimized vitro TH assay for whole brains in 
the previous section had to be slightly modified for these 
samples to accommodate the smaller tissue size and the 
higher activity levels. The brain homogenate was prepared 
by homogenizing the samples with a micro tissue grinder 
(Kontes Glass Co.), which was operated manually. The fol­
lowing ratios were employed: one striatum/250 yl HgO/
25 yl DHBA (4x10 ^ M in 1x10 ^ M  ascorbic acid solution).
As in the whole brain procedure, 250 yl of the homogenate 
was used for each sample. For standard 'homogenates'.
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the following ratios were employed; 25 yl dopa working 
standard/250 yl 8^0/25 yl DHBA (4xlO"^ M in IxlO"^ m  
ascorbic acid solution). The dopa working standard was 
prepared as a 4:100 dilution of the stock standard solution, 
described above for the whole brain procedure, with 1x10 ^
M ascorbic acid. 250 yl of this solution was used in each 
standard as a replacement for the brain homogenate. For 
the blank 'homogenates', the following ratios were employed : 
25 y l  of 1x10 ^ M ascorbic acid/250 y l  H2O/25 yl DHBA 
(4x10 ^ M in 1x10 ^ M ascorbic acid). 250 y l  of this solu­
tion was used in each blank as a replacement for the brain 
homogenate. The remainder of the procedure was identical 
to that described for whole brains.
3. Results and Discussion. The measured ^  vitro 
TH activity after various times of microwave exposure are 
presented in Figure 2.12. The individual values are cal­
culated as a percent of the decapitated results (245+14 
nmol/g/hr) for ease of comparison. As can be seen, the 
TH activity decreases as the time of microwave irradiation 
increases. This is in complete agreement with what was 
expected. At or beyond 250 msec of irradiation, the activity 
is less than 2% of the decapitated values. But, at 300 
msec or more, pressure-induced spreading is observed.
Thus, 250-275 msec irradiation is recommended for routine 












Microwave irradiation time (m sec)
Figure 2.12 TH Activity as a Function of Microwave Irradiation Time.
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II. Simultaneous Determination of vivo TH Activity 
and Endogenous Catecholamines
A. Introduction
The importance of the catecholamines in patho­
physiological conditions (18), Parkinson's disease (19), 
and the affective disorders (20) has been adequately dis­
cussed above. However, under even normal conditions, these 
transmitters are being constantly synthesized, released 
and metabolized. Measurements of this utilization rate, 
or turnover, are, thus, potentially as important as those 
of the endogenous levels. Since tyrosine hydroxylase re­
presents the rate limiting step in the biosynthesis of 
these transmitters, measurement of its vivo rate can pro­
vide us with just such knowledge.
The present procedure determines the ^  vivo TH 
activity by a method similar to that proposed by Carlsson 
and coworkers (13,21). In this technique, a centrally 
active dopa decarboxylase inhibitor is administered to the 
living animals, and the dopa formed by the action of TH 
subsequently accumulates. Since the endogenous level of 
dopa is very low, the dopa measured at a specific time after 
inhibition of the decarboxylase provides a direct determin­
ation of the ^  vivo TH activity. But, the low detection 
limit of the LC/EC allows detection and quantitation of 
very small amounts of dopa. This permits the employment
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of very short times between administration of the blocking 
agent and sacrifice. And, these short time periods provide 
no detectable change in the endogenous levels of NE and 
DA (vide infra). Thus, we can simultaneously measure in 
vivo TH activity, NE and DA.
B. Materials and Methods
The reagents used, along with their preparation 
and/or source, are as follows :
o-MT (a-methyltyrosine) - This was obtained from 
Sigma Chemical Co., St. Louis, MO. The 
solution used for injections, containing 
20 mg/ml, was prepared in deaerated isotonic 
saline (0.15 M NaCl) on the day of use.
MT (methyl ester of a-methyl tyrosine) - This 
was also obtained from Sigma. Solutions 
used for injections, containing 25 mg/ml, 
were prepared in deaerated isotonic saline 
(0.15 M NaCl) on the day of use.
Stock standard solution of dopa, NE and DA - 
This was prepared by dissolving dopa 
(8.0 mg), NE'HCl (8.5 mg) and DA*HC1 (8.0 
mg) in 100 ml of 0.030 M HCIO^. This solu­
tion was never kept over 2 weeks.
The working standard solution - This was prepared 
on the day of use by making a 1:100 dilution
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of the stock standard solution with 0.03 
M HCIO^. One ml of working standard, thus,
contained 80 ng dopa, 70 ng NE and 65 ng
DA. The concentrations of NE and DA are 
expressed here as the free base.
DHBA solution - We first prepared a l.OxlO”^
M (4.4 ng DHBA*HBr/100 ml HgO) stock solution. 
On the day of use, a 1:10 dilution of the
stock solution was made. This second solu­
tion (1x10 ^ was added to tissue samples 
prior to homogenization.
Other chemicals - These were as described above 
for the ^  vitro procedure.
Male mice, treated as described previously for the 
in vitro assay procedure, were employed in all experiments. 
NSD-1034 (200 mg/kg) was injected intravenously a few min­
utes before sacrifice by cervical dislocation. Brains were 
removed as quickly as possible, weighed, frozen with liquid 
nitrogen and stored on dry ice. Each brain was then homog­
enized by either ground glass or ultrasonic homogenization 
in a solution composed of 2.0 ml of 0.050 M HCIO^, 100 pi 
of 1.0 M NaHSOg, 100 pi of 0.10 M EDTA, and 100 pi of
l.OxlO”^ M DHBA. For standards, a 1.00 ml aliquot of the
working standard solution replaced the brain in the above 
mixture. After homogenization, the samples were centri­
fuged at 16,000xg, and 0°C for 15 minutes with storage
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on ice before and after. Following centrifugation, the 
dopa, NE, DA and DHBA in the samples were isolated by 
alumina adsorption and quantitated with LC/EC as previously 
described for the ^  vitro procedure. The dosage of NSD- 
1034 used here, incidentally, was selected from the previous 
work of Pike (3) and is also in agreement with the studies 
using NSD-1015 by Carlsson et al. (13).
Since no blanks are needed for the vivo procedure, 
the calculation of TH activity becomes a little simpler:
(nmol dopa in std)
Dopa formed (nmol/g/hr) = (R-^ J ( H s s u e  wt. g) (time, hr)
where
time = time between injection of inhibitor 
and sacrifice.
The catecholamine levels are calculated as follows (e.g. 
for NE):
All results for multiple determinations are expressed 
as the meant the standard error of the mean (SEM) for at 
least four separate determinations. Statistical comparisons 
are made by using Student's t-distribution.
C. Results and Discussion
The accumulation of dopa for the first six 
minutes after administration of NSD-1034 (200 mg/kg) is 













Figure 2.13 Time Course of Dopa Accumulation in Mouse 
Brain After Treatment with NSD-1034.
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quite linear during this time period. Assuming this repre­
sents the true rate of dopa synthesis, an vivo TH 
activity of 5.6 nmol/g/hr can be obtained from the slope 
of the graph.
In order that the measurement of dopa accumulation 
be a valid indication of the vivo TH activity, the 
dopa should not only be accumulated in a linear manner, 
but it should also be stable. To test the stability of 
the accumulated dopa, two TH inhibitors were used to block 
dopa production after the previous administration of the 
dopa decarboxylase blocker. The TH inhibitors used were 
MT (H44/68, methyl-ester of a-methylparatyrosine) and 
a-MT (a-methylparatyrosine). In these experiments, two 
groups of animals were employed. Both groups were given 
an i.p. injection of the dopa decarboxylase blocking agent 
(NSD-1034 or NSD-1015) at time zero. After a specified 
time interval (5 or 20 minutes), the first group was sacri­
ficed and the second group was given an i.p. injection of 
the TH blocking agent (a-MT or MT). The results are pre­
sented in Tables 2.14 to 2.18; the results from Tables 2.14 
and 2.17 have also been presented in Figure 2.14. The inter­
pretation of these results is independent of either the dopa 
decarboxylase or TH inhibitor employed. Using the 5 minute 
interval, a significant increase in dopa is observed after TH 
blockade. Using the 20 minute interval, a significant
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TABLE 2.14
Stability of Accumulated Dopa after NSD-1034 and MT.
Group Time Schedule (min) Dopa formed
0 5 10
(nmol/g)
1 NSD-1034 Killed 0.38+0.03
2 NSD-1034 MT Killed 0.53±0.03
♦Different from group 1 (P<0.01)
TABLE 2.15
Stability of Accumulated Dopa after NSD-1034 and a-MT.
Group Time Schedule (min) Dopa formed
0 5 10
(nmol/g)
1 NSD-1034 Killed 0.47+0.03
2 NSD-1034 a-MT Killed 0.64±0.06
♦Different from group 1 (P<0.01)
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Stability of Accumulated Dopa after NSD-1034 and o-MT.
Group ______ Time Schedule (min)______ Dopa formed
(nmol/g)
0 20 40
1 NSD-1034 Killed 1.70+0.23
2 NSD-1034 o-MT Killed 0.66+0.17
♦Different from group 1 (P<0.001)
TABLE 2.17
Stability of Accumulated Dopa after NSD-1015 and MT.
Group Time Schedule (min) Dopa formed
0 5 10
(nmol/g)
1 NSD-1015 Killed 0.31±0.02
2 NSD-1015 MT Killed 0.3910.02
♦Different from group 1 (P<0.05)
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TABLE 2.18
Stability of Accumulated Dopa after NSD-1015 and MT
Group Time Schedule (min) Dopa formed
0 20 40
(nmol/g)
1 NSD-1015 Killed 0.98±0.02
2 NSD-1015 MT Killed 0.68+0.06*
♦Different from group 1 (P<0.02)
decrease in dopa is observed after TH blockade. Neither 
of these represent the desired result, which would have 
indicated no change in dopa regardless of the time interval. 
Nonetheless, these results may be practically explained as 
follows. At the 5 minute interval, the TH blocking agent, 
possibly, does not penetrate the nervous system rapidly 
enough. This means its effective blockade is very small 
at very short times after injection (<1 min), reaching 
virtually 100% blockade only towards the end of the 5 minute 
period. The decline in dopa observed at the 20 minute 
interval indicates that dopa is, indeed, being metabolized 
and/or transported out of the brain at very long times. 
Assuming these explanations are fairly accurate, the 5 
minute time for measurement of dopa accumulation still 









tNSD-1034 or NSD-1015 200 mg/kg Î MT500 mg/kg
Figure 2.14 The Effect of TH Inhibition on Dopa Accumulated 
After NSD-1034 (or NSD-1015) Treatment.
NSD-1034 (or NSD-1015) was injected i.p. at 
zero time to two groups of animals. One group 
was killed after 5 minutes. Simultaneously, 
the second group received MT (TH inhibitor). 
The second group of mice were killed after 
another 5 minutes. Dopa content was then 
measured for both groups.
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Determining catecholamine levels at the same time
as measuring dm vivo TH activity demands that these levels
not change while dopa is being accumulated. Of course,
over a long period of time this is impossible. The de-
«
carboxylase agent is blocking the synthesis of the catechol­
amines, while catabolism and transport is not being affected. 
But, in the very short times, it may be possible to see 
no significant decrease in catecholamine levels. Thus, 
we decided to examine the endogenous levels of these amines 
at times up to 6 minutes after blockade of dopa decarboxylase. 
As seen in Table 2.19, there is no significant decline in 
NE or DA during the first six minutes after NSD-1034 ad­
ministration. This means we can use the blockade of dopa 
decarboxylase at times up to six minutes for the simul­
taneous determination of dm vivo TH activity, NE, and DA.
We would not recommend this procedure for any de­
finitive measurements of NE and DA in any particular in­
vestigations. But, it should be completely reliable for 
in vivo TH measurements. And, it should be generally 
applicable as a routine procedure for the simultaneous 
assessment of d^ vivo TH activity, NE, and DA.
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TABLE 2.19











0* 0.01 0.00 1063+81 330+18
2 0.28 0.02 917±96** 328±14**
4 0.45 0.04 1042+52** 320113**
6 0.55 0.06 1096±49** 335126**
*For zero time, mice were given an injection of isotonic 
saline and sacrificed 4 minutes later.
**There are no significant differences (P>0.05) between the 
NE and DA levels at 0 minute when these are compared to 
the results obtained at the other times shown in the table.
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CHAPTER 3
DETERMINATION OF TRYPTOPHAN HYDROXYLASE vitro 
BY LIQUID CHROMATOGRAPHY WITH ELECTROCHEMI­
CAL DETECTION
I. Introduction
Tryptophan hydroxylase (TPH) exhibits a number of 
similarities to the previously investigated tyrosine 
hydroxylase (TH). Notably, both of these enzymes represent 
the rate limiting step in the biosynthesis of their asso­
ciated transmitters. Their activities are, thus, pre­
dictably low in mammalian tissues. This means that only 
highly sensitive analytical methodologies will be capable 
of quantitating these activities. As with TH, TPH activity 
measurements have relied heavily upon fluorescence and 
radiochemical procedures. The fluorescence procedures, 
however, have seen much less frequent utilization in the 
recent past due to their lack of selectivity and relatively 
high detection limits. The radioassays, on the other 
hand, are quite rapid in routine applications and offer 
reasonably good detection limits. But, radioassays require 
the use of labelled chemicals and can exhibit selectivity
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problems. Thus, we decided to see if liquid chromatography 
with electrochemical detection (LC/EC) might be applicable 
to the determination of TPH activity.
II. Development of the Assay
The analysis of TPH activity in tissue samples can 
be viewed as a three step process for simplicity. After 
incubation of the enzyme under appropriate conditions, the 
product is isolated in some type of clean-up procedure.
The isolated product is then quantitated using appropriate 
instrumentation. As is the case with most analyses, these 
steps were developed in reverse order. The final step 
must be firmly established to assess the effects of modifica­
tions in the preceding steps.
In this report, we will begin with a brief outline 
of the materials and the preliminary procedure. This will 
be followed, in order, by detailed discussions of investiga­
tions concerning the LC/EC conditions, the isolation pro­
cedure, and the optimization of incubation parameters.
We will conclude with a discussion of the finally derived 
method for the determination of vitro TPH activity.
A. Materials.
1. Apparatus.
a. Liquid Chromatograph - The liquid chromato­
graph with electrochemical detector has 
been adequately described in general terms
99
in Chapter 1. Several modifications 
were attempted before the system used 
in the optimization studies was selected. 
This system had the following notable 
characteristics :
Column: 5 y, reverse phase. Ultrasphere. 
Mobile Phase : pH 3.0 solution con­
taining 0.15 M citric acid, 0.025 
M sodium citrate, 0.15 M acetic 
acid, and 0.025 M sodium acetate. 
Flow Rate: 0.63 ml/min.
Detector Potential: 0.65 V vs. Ag/AgCl.
b. Isolation Column - The column used to 
isolate the product of hydroxylation was constructed from 
a Pasteur pipet. The tip was first loaded with a small 
glass wool plug, which served as a bed support. A portion 
of the pipet, 2 mm in diameter, was filled to a height
of ca. 20 mm with Bio-Rex AG 50W-X2 cation exchange resin. 
The columns were prepared for use by washing with 1.0 ml 
of 0.10 M HCl.
c. Other Equipment - All other equipment is 
described in Chapter 2.
2. Animals. The animals and their housing are 
described in Chapter 2.
3. Chemicals and Sources.
Catalase - Grade C-30, 21,000 unit/mg, 25 mg/ml.
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Obtained from Sigma Chemical Co., St.
Louis, MO.




L-Tryptophan - Regis Chemical Co., Morton 
Grove, IL.
5-Hydroxytryptamine (Serotonin Creatinine 
Sulphate, 5-HT) - Aldrich.
Other Chemicals - See Chapter 2.
4. Solutions.
5-HTP - A stock standard solution was prepared 
by dissolving 3.75 mg 5-HTP in 50 ml of 
deaerated 0.10 M HCl. On the day of use, 
a working standard was prepared by diluting
1.00 ml to 25.00 ml with 1x10  ̂M ascorbic 
acid.
5-HT - A stock standard solution was prepared
by dissolving 8.63 mg of serotonin creatinine 
sulfate in 50.00 ml of deaerated 0.10 M 
HCl. On the day of use, a working standard 
was prepared by diluting 1.00 ml to 25.00 ml 
with 1x10  ̂M ascorbic acid.
NM-5-HT - A solution of NM-5-HT was prepared 
by dissolving 12.2 mg of the salt in 50 ml
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of deaerated 0.10 M HCl.
Elution Solution - A solution containing 0.40 M 
NaOH in a 50:50 mixture of ethanol and water 
was prepared for elution of 5-HTP and NM-5-HT 
from the cation exchange column used in the 
isolation step.
B. Data Treatment. The calculation of tryptophan 
hydroxylase activity is analogous to that described for 
tyrosine hydroxylase in Chapter 2. All results are expressed 
as the mean ± the standard error of the mean (SEM) for at 
least four separate determinations. Statistical comparisons 
employed Student's t-distribution (3).
C. Initial Procedure. After sacrificing the animals 
by cervical dislocation, the brains were quickly removed, 
weighed and stored on ice. The tissue was homogenized
in distilled water containing the internal standard in 
the following proportions:
1 brain/3.00 ml HgO/SO yl of NM-5-HT.
The incubation mixture consisted of the following 
components in a total volume of 500 pi. The concentration 
of the components in the final mixture is given in paren­
theses: 100 pi of pH 7.6, 2.0 M acetate (0.40 M ) ; 50 pi
of a solution which is 2.0 mM in 6-MPH. (0.20 mM) , 1.0 M 
in 2-mercaptoethanol (0.10 M), 4.0 mM in NSD-1015 (0.40 
mM), and which also contains 420 unit of calalase (0.84
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unit/y 1) ; 50 yl of 1.0 itiM ferrous sulfate (0.10 mM) ; 200 yl 
of the brain homogenate; 50 yl of 1.0 mM L-tryptophan 
(0.10 mM) ; and, 50 yl of 1.0 irM ascorbic acid (0.10 mM) .
For standards, 50 -yl of the 5-HTP working standard 
replaced the ascorbic acid solution in the above incubation 
mixture. Also, 50 y l  of 60% HClO^ was added prior to in­
cubation. Blanks were obtained by simply adding 50 y l  of 
60% HCIO^ to the above incubation mixture prior to incubation.
The incubation mixture was placed in an uncapped, 
vertically positioned centrifuge tube, and incubation was 
carried out at 37“C for 30 minutes. The shaker was set 
at the low shaking rate. The reaction was terminated by 
the addition of 50 yl of 60% HClO^ to the samples. The 
reaction mixture was centrifuged at 27,750xg and 4“C for 20 
minutes with storage on ice before and after. 50 yl of the 
supernatant was transferred to a cation exchange isolation 
column. The column was washed by treatment with 1.0 ml of
0.1 M HCl. This was followed by 250 yl of saturated KCl 
in 0.1 M HCl and 200 yl of distilled water, respectively.
100 yl of elution solution was added to the column and the 
eluate collected in a small vial containing 25 yl of 4.0 
M HCl. 5 yl of the elute was finally injected into the 
LC/EC system for quantitation of the 5-HTP produced.
D. Liquid Chromatographic Conditions. In the initial 
stages of this investigation it was hoped that we might
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be able to eliminate the isolation procedure. Incubation 
would be followed by only acid precipitation of the proteins, 
centrifugation, and injection of the supernate into the 
LC/EC. The high resolution (5 y) reverse phase columns 
were considered, but rejected, for this purpose. It was 
anticipated that these columns would be clogged by multiple 
injections of the rather crude supernates. Instead, we 
selected the Vydac CX columns. Such materials have a much 
larger particle diameter and, are, thus, less susceptible 
to clogging problems. This material had previously been 
shown to possess considerable retentive properties for 
indole compounds, while exhibiting much less retention of 
catecholamines and virtually no retention for acidic and 
neutral metabolites.
Several different conditions were attempted for the 
separation of the compounds of interest before a 500x3 mm 
column with a mobile phase containing 0.050 M HCl and
0.30 M KCl was found to provide the desired separation.
A chromatogram for a typical incubation mixture is shown 
in Figure 3.1. While adequate for routine applications, 
this chromatogram also reveals the unanticipated appearance 
of 6-MPH^. The peak for 6-MPH^ is completely separated 
from the others, but its presence adds a considerable 
amount of time to the quantitation of individual samples.
To make these determinations more applicable to routine 
determinations, we decided to shorten the chromatogram
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a.
Figure 3.1 A Typical Chromatogram for a TPH Assay by 
Direct Injection into a Vydac Cation Exchange 
Column.
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by eliminating the 6-MPH^ peak. This was attempted by 
both chemical and instrumental means.
An investigation of the cyclic voltammetric behavior 
of the compounds involved indicated that the indoles are 
oxidized at ca. +0.6 V. vs. SCE while the cofactor, 6-MPH^ 
is oxidized at ca. +0.3 V vs. SCE. It was, thus, thought 
that it might be possible to find an oxidizing agent, to 
be added after incubation, which might selectively oxidize 
only the cofactor. The agents used represented half­
reactions spanning a standard reduction potential (E°) range 
of +0.34 to +0.69 volts and included Cu^^, Fe(CN)g^, 
and p-benzoquinone. These all proved to be entirely in­
adequate except for p-benzoquinone. This compound did, 
indeed, cause the disappearance of 6-MPH^ from the chromato­
gram. Unfortunately, it was also found that the 5-HTP 
peak gradually deteriorated after treatment with p-benzo­
quinone. Thus, this approach was abandoned.
A second approach to the 6-MPH^ problem employed a 
slightly different mobile phase and column switching. The 
mobile phase (0.050 M HCl containing 0.020 M KCl) coupled 
with a short Zipax SCX precolumn (see Figure 3.2) increased 
the k' value for 6-MPH^ while leaving the k' values for 
other components virtually unchanged. This allows total 
isolation of the 6-MPH^ peak from the rest of the peaks 
seen in Figure 3.1. Adequate resolution of the remaining 

















Figure 3.2 The Use of Column Switching to Separate and 
Discard the 6-MPH. in a TPH Assay.
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original column. This situation is advantageously coupled 
with the column switching arrangement of Figure 3.2. The 
sample is injected with the values set to configuration 1. 
After waiting a specific amount of time, all the compounds 
of interest except 6-MPH^ have passed the outlet of the 
precolumn. At this time, the valves are switched to con­
figuration 2. In the second position, the compounds of 
interest are separated and detected by the main column, 
while the 6-MPH^ is simultaneously flushed from the precolumn. 
This column switching approach effectively cut the individual 
chromatographic times from 30 to 20 minutes. But, accurate 
manual and/or automated control is essential for timing 
purposes. Since we do not currently have such automatic 
control, and the manual timing was difficult to reproduce, 
we decided to examine another possible route to direct 
injection.
The major component of interest in the present in­
vestigation, 5-HTP is an amino acid. Thus, raising the pH 
of the mobile phase considerably would place this compound 
in its anionic form. Employing a-methy1-5-hydroxytryptophan 
as an internal standard, a 500x3 mm Zipax SAX, strong anion 
exchange column packing material, and a pH 9.0 Tris buffer 
(0.30 M containing 0.0010 M NH^NOg), we were, indeed, able 
to produce a usable chromatogram. Individual injections 
could be made every 20 minutes with this arrangement. Un­
fortunately, the high pH of the mobile phase caused the
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resolution of the column to deteriorate in a very short 
period of time. Noticeable changes were seen after routine 
employment of the system for only one week. Another short­
coming of this setup is that it produces a rather large 
solvent peak. This occasionally leads to difficulties in 
the determination of component peak heights.
Judging the above procedures for direct injection 
to be either incapable of or inappropriate for routine 
applications, we decided to try the higher resolution reverse 
phase column combined with an isolation procedure for sample 
clean-up prior to injection in the LC/EC. While recognizing 
that the isolation step would be adding time to the overall 
procedure, it was hoped that the higher resolution might 
also shorten the chromatographic time required for each 
sample. The applicable column conditions (vide supra) did 
just that. Individual samples could be injected every 11 
minutes in the microparticulate columns.
E. Isolation Studies. There have been a number of 
papers which have reported the use of ion exchange beads 
(200 mesh) for the isolation of biogenic amines. Initially, 
trying to isolate 5-HTP with DOWEX 50W-X8, we found that 
the adsorbed compounds were very difficult to desorb due 
to the strong interaction between the indole ring and the 
styrene-divinylbenzene copolymeric substructure of this 
resin. Thus, we were encouraged by the reported isolation
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of tryptophan from rat brain tissue on DOWEX 50W-X2 by 
Koch and Kissinger (2). Using this resin, we were also 
able to isolate the desired 5-HTP and NM-5-HT (internal 
standard). However, our eluting solvent, 0.40 M NaOH in 
a 50:50 mixture of ethanol and water, was a bit stronger 
than the 0.10 M NH^ reported by these authors.
Using this isolation procedure, we examined the per­
cent recovery and linearity of 5-HTP and NM-5-HT. For these 
studies, incubation mixtures with various added amounts 
of 5-HTP and a fixed amount of NM-5-HT were subjected to 
the isolation procedure prior to LC/EC quantitation. These 
samples were compared to pure solutions of 5-HTP and NM-5-HT 
which were directly injected. The results are presented 
in Table 3.1.
The linearity of peak height ratio (Hg.HTp/HQM.g.HT) 
as a function of the amount of 5-HTP added to the incubation 
mixture (constant amount of added NM-5-HT) was also investi­
gated. The results are shown in Figure 3.3. As can be 
seen, linearity is exhibited over the usual operating range 
of 10-190 ng (47-950 pmol).
A chromatogram obtained from a routine sample of 
whole mouse brain employing the usual incubation along with 
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Figure 3.4 A Typical Chromatogram for the TPH Assay Using 
a Reverse-Phase, Microparticle Column.
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TABLE 3.1
Recovery of 5-HTP & NM-5-HT from Incubation Mixtures 





F. Optimization of Incubation Parameters. The optimum 
condition for any single parameter can be interpreted in 
two ways. One is simply that condition which provides the 
maximum observed activity, expressed as nmol/g/hr. The 
second is that condition which provides the maximum signal/ 
noise, or tissue/blank, ratio. The parameters for the 
present TPH assay were primarily optimized for maximum ob­
served activity, although signal/noise ratios were also 
monitored as appropriate. The ordering of these optimization 
studies, incidentally, is important. The optimal condition 
for a given parameter, once found, was incorporated into 
all succeeding investigations.
All concentrations in this section are with respect to the 
final incubation mixture.
1. Buffer Type. Three major buffer systems were
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considered for this assay procedure: acetate, Tris and
phosphate. The latter two would provide much better buffering 
in the generally accepted pH optimum range of 7.0 to 8.0.
But, previous reports have indicated that phosphate inhibits 
TPH. Tris has been used by some authors (4), although 
it is also reported to be inhibitory (6). Nonetheless, we 
compared acetate to Tris. The results (79.1±1.2 vs .
65.1±3.4, respectively) clearly show the acetate buffer 
to be better. Thus, acetate was used in all subsequent 
experiments.
2. Divalent Cation. Stimulation of TPH in tissue
+2homogenates has been claimed in the presence of Fe and,
+2more recently, in the presence of Ca (7,8,13). The re­
sults for the present investigation of these cations is
presented in Table 3.2. Not only is the activity of TPH
+2higher in the presence of 10 mM Ca , but the blank values
+2 4"2are noticeably lower than with Fe . Thus, 10 mM Ca
was selected as the optimal divalent cation concentration.
Many other studies, it should be noted, have found that
+2TPH activities are not greater when 100 mM Ca is used
+2instead of 10 mM Ca . Thus, higher concentrations were 
not examined in the present study.
3. Buffer pH. Knapp et al. (7) reported that
TPH not only provided improved activity in the presence 
+2of Ca , but it also exhibited a shift in its pH maximum
+2when compared to Fe . Being somewhat intrigued by this
TABLE 3.2
Effect + 2 +2 of Fe and Ca on TPH Activity* and Blank Values
Ion Concentration
(mM)
psample TPH Activity (nmol/g/hr) ^blank
Signal/Noise
none G 0.417±0.010 49.5±2.1 0.062±0.003 5.7
Fe^^ 1 0.655±0.048 77.8±6.5 0.077+0.004 7.5
ca+: 0.1 0.404+0.010 58.7+1.9 0.065+0.002 5.2
1 0.487+0.012 70.8+5.1 0.067+0.007 6.3
10 0.756±0.023 102.1+3.3 0.064±0.003 10.8
*pH of incubation mixture was 7.60.
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report, we proceeded to examine the pH maximum for TPH
in the presence of each of these cations independently.
As seen in Figure 3.5, our results support the previous 
+2data. With Fe , the maximum occurs at a pH of 7.7-7.8,
+2whereas with Ca it occurs at 8.0. Thus, a pH of 8.0 
was selected for all following measurements. We must also 
point out, however, that the acetate buffer is virtually 
devoid of buffering capacity at this value. Thus, a 
search for a buffer with a greater capacity around pH 8.0,
i.e., one having a pK^ in the vicinity of 8.0, but without 
the inhibitory properties of Tris or phosphate, might still 
be a worthwhile venture.
4. 2-Mercaptoethanol. This reagent has been re­
ported to function as both a protein activator (9) and a 
reducing agent. In the present assay, as seen in Figure 
3.6, a relatively low concentration (0.020 M) produced
a dramatic increase in the activity of TPH. Higher con­
centrations, however, exhibit an inhibitory effect. The 
highest concentrations, i.e., greater than 0.10 M, also 
resulted in the appearance of several unidentified peaks 
in the final chromatogram. However, at the optimal con­
centration of this reagent, no such interferences were 
observed.
5. 5-Hydroxytryptophan Decarboxylase Inhibitor.
The decarboxylase inhibitor, NSD-1015, produces a small 
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Figure 3.6 The Effect of 2-Mercaptoethanol on TPH Activity.
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However, higher concentrations resulted in inhibition of 
TPH activity. From this effect of NSD-1015 on TPH activity, 
shown in Figure 3.7, 0.010 it̂  was chosen as the optimal 
value.
6. Pterin Cofactor. The effect of the pterin
cofactor, 6-methyltetrahydropterin (6-MPH^), on TPH activity,
is shown in Figure 3.8. The inset plot of 1/V vs. 1/S
indicates a V of 154 nmol/g/hr and a K of 0.34 mM.max m —
From these results, the minimal saturating concentration 
was estimated to be 0.50 mM. 6,7-Dimethyltetrahydropterin 
(DMPH^) was also investigated for use as the pterin cofactor. 
But, our results, in agreement with a previous report (5), 
showed this agent to be much less effective than 6-MPH^.
7. Catalase. In contrast to the lack of effect 
of catalase on TH activity observed in Chapter 2, catalase 
definitely does exhibit a stimulating effect on TPH activity. 
As can be seen from Figure 3.9, catalase, at concentrations
5.25 unit/vil or greater, produce maximal activity. Therefore,
5.25 unit/yl was chosen for subsequent utilization.
8. Substrate. From the previous work on tyrosine 
hydroxylase, we anticipated that the concentration of L- 
tryptophan would affect both the rates of enzymatic and 
non-enzymatic 5-HTP production. We, therefore, used in­
dividual sets of samples, standards and blanks for each 
level of tryptophan investigated. The results are plotted 
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Figure 3.10 The Effect of the Substrate Concentration 
on the Rate of 5-HTP Formation.
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into account an endogenous tryptophan concentration of
6.1 Tig/g, yields a V of 133 nmol/g/hr and a K of 0.15ItiaX itl
mM. Thus, subsequent studies employed the estimated minimal 
saturating concentration of 0.40 mM L-tryptophan.
9. Incubation Time. The amount of 5-HTP formed 
as a function of the incubation time is shown in Figure 
3.11. From this, an optimal value of 25 minutes was 
selected.
10. Preincubation Time. Preincubation of all com­
ponents except the substrate has been shown to increase the 
observed activity for many enzymes. However, as presented 
in Figure 3.12, this was not the case for TPH. Therefore,
no preincubation was used in the following TPH investigations,
11. Incubation Temperature. Identical groups of 
samples were incubated for the same period of time at dif­
ferent incubation temperatures. The results are shown in 
Figure 3.13. From this graph, it was apparent that in­
cubation at 37°C gives the highest activity. This incuba­
tion temperature was, thus, selected as optimal.
12. Enzyme Concentration. An investigation of 
TPH activity as a function of the amount of added enzyme, 
expressed as the volume of added brain homogenate, was 
undertaken to ascertain the absence of endogenous inhibitors. 
As can be seen from Figure 3.14, the activity observed was 
linearly dependent on the amount of enzyme added to the 
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Figure 3.14 The Amount of 5-HTP Formed as Function of the 
Volume of Brain Homogenate Added to the 
Incubation Mixture.
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mixture is adequate for routine utilization.
13. Summary. The parameters optimized, ranges 
investigated, and the resulting optimal conditions are 
presented in Table 3.3.
G. Final Procedure. The vitro tryptophan hydroxylase 
procedure presently believed to yield optimal activity and 
signal/noise ratios is obtained by using the optimized 
values of Table 3.3 in the initially presented procedure. 
Employing these values, a typical assay produced a result 
of 81.0±0.6 nmol/g/hr for whole mouse brain. Since there 
are no directly comparable results found in the literature, 
we decided to examine the similarity of the present results 
to those obtained for rat brain stem. In rat brain stem.
Gal and Patterson (5) reported 4.0-4.6 nmol/mg protein/hr. 
Meek et al. (4) reported 4.7±0.5 nmol/mg protein/hr, and 
Kizer et al. reported 0.88+0.09 nmol/mg protein/hr.
Assuming a brain protein content of 10%, our value would 
correspond to 0.81±0.01 nmol/mg protein/hr. While not 
being directly comparable, our results can, nonetheless, 
be seen to be quite reasonable. Higher values from rat 
brain stem are to be expected, since this region contains 
a much larger fraction of serotonin-containing neurons 
and thus, presumably, a much larger fraction of TPH than 
the whole brain.
The detection limit of the finally derived procedure
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TABLE 3.3







Buffer type Acetate Acetate, Tris Acetate
Fe^^ 0.1 mM 0.1-1.0 mM None
c a « none 0.1-10 mM 10 mM
Buffer pH 7.6 7.2-8.4 8.0
2-Mercapto­
ethanol 0.10 M 0-0.60 M 0.020 M
NSD-1015 0.40 mM 0-1.0 mM 0.010 mM
6-MPH. 0.20 mM 0.10-1.0 mM 0.50 mM4
Catalase 0.84 unit/yl 0-5.25 unit/yl 5.25 unit/yl
L-Tryptophan 0.10 mM 0.010-0.60 mM 0.40 mM
Incubation
Time 30 min 5-60 min 25 min
Preincubation 0 min 0-30 min 0 min
Temperature 37°C 34-45°C 37°C
*Fixed parameters:
Shaking rate - slow, 3.0 cycle/sec.
Incubation tube orientation - vertical, uncapped.
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appears to be slightly better than those previously re­
ported. Employing a minimal signal/noise ratio of two, 
we can currently detect about 0.2 ng, or 1 pmol, of 5-HTP 
produced. This corresponds to the determination of TPH 
activity in as little as 6 yg of rat brain stem assuming 
a 55% recovery in the isolation step. This is compared 
to the 5-HTP detection limit of 20 ng, or 100 pmol, reported 
for the fluorometric assay of Gal and Peterson (5), and 
the detection limit of 0.5 ng, or 2.5 pmol, reported for 
the radioenzymatic procedure of Kizer et al. (11).
The LC/EC procedure also exhibits a greater selecti­
vity than these alternative methods. Endogenous and exo­
genous indolic compounds may interfere in either the fluoro­
metric or radiochemical procedures. But, at the present 
time, none of these species is known or anticipated to 
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CHAPTER 4
A RAPID AND SENSITIVE PROCEDURE FOR THE DETER­
MINATION OF SEROTONIN IN MOUSE BRAIN 
TISSUE
I . Introduction
Our laboratory recently became involved in an in­
vestigation of serotonin levels in various regions of 
mouse brain. The number of samples anticipated quickly 
caused us to consider the possibility of a more rapid pro­
cedure than the butanol extraction process combined with 
LC/EC quantitation (11). The sensitivity and selectivity 
needed, as well as other practical considerations, still 
indicated the necessity for LC/EC. Thus, we focused our 
attention on shortening or eliminating the butanol isolation 
step. The maximum savings in time, of course, would be 
obtained by a total elimination of this step, and this is 
where we directed our initial efforts.
The liquid chromatography employed for these studies 
was of the rather low resolution, large particle size (30- 
40 y) variety. This selection was based upon two major 
criteria. The alternative high resolution, small particle
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size column (5 y) would be expected to offer a considerable 
increase in efficiency. But, such high resolution is not 
necessarily required when one is only concerned with a 
single compound. And, we anticipated that the smaller 
particle size would lead to more frequent clogging problems 
when injecting supernates from brain homogenates directly 
into the chromatograph.
The remainder of this chapter discusses the develop­
ment and application of a procedure for serotonin which 
employs only homogenization, centrifugation, and quantitation 
by LC/EC. The isolation step is eliminated from the usual 
procedure.
II. Materials and Methods
A. Materials
1. Apparatus.
a. LC/EC. The liquid chromatograph with 
electrochemical detection has been discussed in general 
in Chapter 1. The present system is composed of the 
following specific components:
Pump - Milton Roy Minipump, Model 13906-1. 
Column packing - Vydac CX, pellicular
(30-40 ym) cation exchange resin from 
The Separation Group, Hesperia, CA.
Zipax sex - pellicular (30-44 ym) cation 
exchange resin from Dupont Instruments, 
Wi Imington, DE.
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Columns - composed of glass: 250x3 mm,
150x3 mm, and 500x3 mm obtained from 
Altex, Inc., Santa Barbara, CA.
Detector - Home-made as described in Chapter 
1.
Chromatographic Conditions -
Mobile Phase: Citrate/acetate buffer,
pH 5.1, containing 0.025 M citric acid, 
0.050 M sodium acetate, 0.060 M NaOH, 
0.020 M acetic acid, and 0.20 M NaCl. 
Flow Rate: 1.0 ml/min.
Detector Potential: 0.65 V vs. Ag/AgCl.
Column: 500x3 mm Vydac CX or
250x3 mm Vydac CX + 150x3 mm 
Zipax sex
b. Tissue Homogenizer. The samples were homo­
genized with an ultrasonic cell disrupter. Model W 200P,
obtained from Ultrasonics, Inc. This was equipped with a
long probe tip designed for small volume work.
c. Centrifuge. A Sorvall Model RC2-B, equipped 
with an SM-24 rotor, was used for all centrifugal separations.
d. Centrifuge Tubes. 1.5 ml polypropylene 
tube with V-shaped bottoms were used to house samples 
during homogenization and centrifugation.
2. Animals. See Chapter 2.
3. Reagents. See Chapters 2 and 3.
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4. Solutions.
a. Stock standard solution - 8.63 mg of serotonin
creatinine sulphate was dissolved in 50 
ml of deaerated 0.10 M HCl.
b. Working standard solution - On the day of
use, 1.00 ml of the stock standard solu­
tion was diluted to 100 ml with deaerated 
0.10 M HCl to give a solution containing 
750 ng 5-HT/ml (expressed as the free 
base).
c. Internal standard stock solution - 12.2 mg
of N^-methyl-5-hydroxytryptamine oxalate
(NM-5-HT) was dissolved in 50 ml of
deaerated 0.10 M HCl to give a solution
-4having a concentration of ca. 9x10 M.
B. Routine Procedure. The method described in this 
section is directly applicable to the routine determination 
of serotonin in whole mouse brain. The development of this 
method is discussed in the immediately following sections.
After sacrificing the animals, the brains are removed 
as quickly as possible, placed in small polypropylene centri­
fuge tubes, frozen in liquid nitrogen and stored on dry 
ice. At the time of analysis, the small centrifuge tubes 
containing the brains are weighed. To each tube, 750 pi 
of a homogenizing solution is added. The homogenizing
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solution is prepared by diluting 200 pi of the stock NM-5-HT 
solution to 50 ml with deaerated 1.0 M HCl. Homogenization 
of the tissue is accomplished with the ultrasonic cell dis­
rupter, set for 20 sec at a 50% pulse rate and a medium 
(No. 6) output power rating. The homogenate is then cen­
trifuged at 27,750xg and 4°C for 30 minutes. Finally, about 
5 yl of the supernate is injected into the LC/EC for 
quantitation.
For standards, 450 yl of a working standard solution 
is used to replace the brain in the above procedure. After 
thorough mixing this solution is injected directly into 
the LC/EC without being subjected to the ultrasonic 
treatment.
Each of seven individual mouse brain parts may also 
be analyzed by a procedure similar to that outlined for 
the whole brain. Some of the parameters used for the whole 
brain, however, require modification to make them more 
appropriate to the brain parts. A summary of the reagents 
applicable to whole mouse brain and brain parts is pre­
sented in Table 4.1.
C. Data Treatment. The 5-HT level in a tissue sample 
is established by comparing the peak height ratio of 5-HT 
and the internal standard for the sample to the average 
ratio for the standards;
5-HT (ng/g, = tgf
TABLE 4.1
Reagents Used in the Determination of Serotonin in Mouse 
Brain Parts
Whole Brain and
Brain Parts Standard Sample
Working^^ Internal^ 
Std (pi) Std (pi)






.0 M HCl 
(pT)
Diencephelon 50 200 0 44 200 0
Hippocampus 50 150 50 33 150 50
Cerebellum 50 100 100 57 100 100
Medulla-pons 50 200 0 43 200 0
Midbrain 50 200 0 36 200 0
Striatum 50 150 50 23 150 50
Cortex 200 150 150 198 150 150
Whole brain 450 750 0 450 750 0
w
♦Internai standard is a 1:250 dilution of the stock NM-S-HT solution in deaerated
1.0 M HCl.
♦♦Working standard is a 1:100 dilution of the 5-HT stock standard solution in 
deaerated 0.10 M HCl.
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hero p = /Peak height of 5-HT for sample .
sample Peak height of NM-5-HT for sample^
_ _ .Peak height of 5-HT for std .
std Peak height of NM-5-HT for std ave
All results for multiple determinations are expressed 
as the mean ± the standard error of the mean (SEM) and re­
present at least five separate measurements. Statistical 
values were calculated using Student's t-distribution (1).
III. Development of Procedure
A. Chromatographic Conditions. In implementing a 
direct injection scheme for the analysis of 5-HT, a number 
of potentially interfering compounds must be considered.
From previous work (11), it was known that the compound 
of interest, 5-HT, would be highly retained by a styrene- 
divinylbenzene based cation exchange resin such as Vydac 
SC. We, thus, proceeded to investigate the use of such 
a column. After trying a variety of conditions, it was 
found that a 500x3 mm column with a mobile phase consisting 
of a citrate/acetate buffer and a high concentration of 
NaCl would provide the desired separation of 5-HT and the 
internal standard, NM-5-HT. The high ionic strength of the 
mobile phase shifts essentially every potentially interfering 
cationic species to the solvent front. Potential inter­
ferences of the amino acid, neutral, and acidic variety are 
not retained due to the nature of the packing material and 
the pH of the mobile phase. A typical chromatogram for a 
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Figure 4.1 A Typical Chromatogram Obtained From a Whole 
Mouse Brain 5-HT Assay.
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However, Ponzio and Jonsson (2) had previously used 
a 2.1x200 mm Vydac CX column with a citrate/acetate mobile 
phase for the determination of 5-HT and reported that the 
dopamine metabolite, 3-methoxytyramine, interfered with 
5-HT. This was particularly of concern for brain regions 
with a dense dopaminergic innervation such as the neostriatum. 
Using the present chromatographic conditions, as seen in 
Figure 4.2, however, no such interference was observed. The 
3-methoxytyramine (3-MT) is clearly separated from 5-HT.
It should be mentioned that, after this work was com­
pleted, the use of a combination of column materials was 
found to provide an even better separation than that pre­
sented above. Thus, a tandem arrangement of Zipax SCX,
150x3 mm, and Vydac SC, 250x3 mm, is now being routinely 
employed in our laboratory. The Zipax provides a better 
resolution for 5-HT and NM-5-HT, while the Vydac provides 
the necessarily strong retention of both.
B. Attempted Whole Brain Analysis. During the initial 
phase of this study, a 0.025 M HCl solution was employed 
as the homogenizing medium. To our surprise, this resulted 
in a measured 5-HT level of 300 ng/g for the whole mouse 
brain. As seen in Table 4.2, the average reported value 
for 5-HT is more like 500-800 ng/g. This direct injection 
approach, involving no clean-up or isolation step pro­
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Figure 4.2 A Typical Chromatogram Obtained During the 
Determination of 5-HT in Mouse Brain Striatum,
TABLE 4.2
Whole Mouse Brain 5-HT Levels Reported by Various Workers
Investigator Technique Homogenizing Medium 5-HT (ng/g)
Carlsson et al. (16) Fluorescence 0.40 M HCIO^ 520
Leroy (15) II 0.10 M HCl 520±16
Weintraub et al. (10) GC/MS - 670+40
Sasa & Blank (11) LC/EC 0.025 M HCl 805+12
Fleming et al. (5) Fluorescence acetone 550±10
Wiegand and Perry (6) II 0.010 M HCl 820+12
Welch and Welch (7) II 0.010 M HCl 600-800
Smith (8) II 0.50 M HCl 660+13
Agrawal et al. (9) II - 410±16




which was equal to or greater than the previous results.
This led us to investigate the only chemical parameters, 
the acid type and concentration, involved in the homogeniza­
tion.
C. Investigation of Homogenizing Medium. Three dif­
ferent types of acid are typically used for protein precipita­
tion in tissue homogenization; HCl, HCIO^ and ClgCCOOH.
Thus, we determined the 5-HT level of mouse brain using 
various concentrations of these three acids. As seen in 
Table 4.3, indiscriminate selection of either acid type or 
concentration could lead to quite diverse results. The 
5-HT levels measured ranged from 123 to 728 ng/g.
Since deproteinization by acid treatment is so com­
monly employed by investigators, we further examined the 
cause of these variable results. Thus, we investigated the 
percent recovery of 5-HT from different homogenizing mediums. 
For each acid, three groups of samples were prepared according 
to Table 4.4. After thoroughly mixing the samples from all 
groups, those from groups 1 and 2 were centrifuged. An 
accurately measured volume of supernatant from each sample 
in all groups was then injected into the LC/EC, and the 
absolute peak heights of 5-HT were measured. To calculate 
the percent recovery of 5-HT, the difference in the peak 
heights for samples from groups 1 and 2 were compared to 
the peak heights obtained for group 3. The resulting
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TABLE 4.3
The Effect of Acid Concentration in the Homogenizing Medium 






1.1 712112 61319 683118
0.57 728+19 588126 689126
0.11 667127 689133 705133
0.057 575111 52317 634111
0.014 47917 14616 261115
0.0057 354112 12315 151116
*Each brain was homogenized in 750 pl of the listed acid con­
centration and composition containing an appropriate amount 
of NM-5-HT.
percent recovery of 5-HT for the three acids investigated 
is presented in Figure 4.3. Comparable, although not 
exactly equivalent, results were obtained for NM-5-HT.
Based on this data, an HCl homogenizing medium of 0.50 to
1.0 M was selected to be optimal for routine applications.
Sasa had previously reported (12) that a direct 
injection of the supernate in the determination of dopamine 
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Figure 4.3 The Effect of Different Concentrations of 




Composition of Samples Used to Determine the Percent 




Brain homogenate* 500 yl 500 yl
NM-5-HT** 100 yl 100 yl 100 yl
5-HT*** 100 yl 100 yl
X M HA**** 100 yl 500 yl
♦Several brains were pooled together in a ratio of 1 brain 
per 1.5 ml homogenizing acid solution, where the homogenizing 
acid investigated is HA and its concentration is x M. 
Homogenization was effected with ultrasonic disruption (out­
put setting No. 6, 20 sec/brain).
**NM-5-HT was prepared as a 1:50 dilution of its stock 
solution in deaerated homogenizing acid (HA) of concentration 
X M.
***5-HT was prepared as a 1:100 dilution of the stock 
standard solution in deaerated homogenizing acid (HA) of 
concentration x M.
****HA is the acid investigated (HCl, HClO^, or CClgCOOH).
The concentration examined is x M.
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chromatographic resolution after only ten injections. Our 
initial studies, using the same acid concentration (0.025 
M HCl) for deproteinization had also resulted in rather 
rapid worsening of the column performance. Further investiga­
tions, however, revealed that this performance was also 
largely related to the acid strength of the homogenizing 
medium. As can be seen from Figure 4.4, a 1.0 M HCl homo­
genizing medium not only yields the highest recovery of 
5-HT, but also provides a much better column performance.
Using the 1.0 M HCl, hundreds of samples can be injected 
without the column showing signs of significant deterioration.
D. Sonication Effects. The only other homogenizing 
parameter is represented by the fact that the samples are 
sonicated to elicit homogenization. This was of some con­
cern since Alliger (14) had reported that extensive ultra­
sonic treatment could produce destruction of the indole 
nucleus of tryptophan. To investigate the possible effect 
of ultrasonic treatment on 5-HT and NM-5-HT, we decided to 
first examine treated and untreated standard samples.
These samples were prepared as described in the Materials 
and Methods section of this chapter and divided into two 
groups. One group was ultrasonically treated (power setting 
6, 40 sec, 50% duty cycle) while the other was not. The 
results are shown in Table 4.5. As can be seen, sonication 
significantly affects both the peak heights and the peak
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Figure 4.4 Chromatograms from Whole Mouse Brain 5-HT 
Assays, a. Brain homogenized in 1,0 M HCl;
b. Brain homogenized in 0.10 M HCl.
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TABLE 4.5
The Effect of Ultrasonic Treatment on 5-HT and NM-5-HT
Ultrasonic
Treatment




No 99.6+0.9 74.8+0.65 1.3310.01
Yes 50.4+1.9 32.8±1.7 1.54+0.06
P-value P <0.001 P <0.001 P <0.001
height ratio for 5-HT and NM-5-HT.
Having observed these rather disturbing effects of 
sonication upon standards, we proceeded to examine the same 
for tissue samples. The individual samples were prepared 
as described in the Materials and Methods section of this 
chapter. Different groups of samples were subjected to 
different times of sonication. The results are shown in 
Table 4.6. From this data, the peak height for 5-HT is 
seen to exhibit a maximum at 21 sec. Therefore, a sonication 
time of 21 seconds was used for all subsequent investigations,
Once the optimal sonication time for tissue samples 
was obtained, we proceeded to examine if sonication at 
this value might differently effect the percent recovery 
of 5-HT and NM-5-HT in the samples and standards. For this 
study, four groups of samples are prepared according to
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TABLE 4.6
The Effect of Sonication Time on Peak Heights and Peak 
Height Ratio for 5-HT and NM-5-HT 
in Mouse Brain Tissue
Peak Height or Sonication Time (sec)**
Peak Height Ratio* 8 21 42 64 86
H5-HT/SBmple wt 177+7 199±9 188±10 167±7 156±15
^NM-5-HT 53±2 51±1 47±3 45+3 40±5
®5-HT/^^NM-5-HT*
Sample Wt) 3.33 3.90 4.00 3.71 3.90
*Peak heights (H) given in mm.
**Medium (No. 6) power setting ; 50% duty cycle •
TABLE 4.7
Composition of Samples Used to Investigate the Percent
Recovery of 5-HT and NM- 5-HT in the Absence
and Presence of Brain Tissue After Sonication
Reagents Group
1 2 3 4
Brain Homogenate,* pl 500 500
NM-5-HT, pl 100 100 100 100
5-HT, pl 100 100 100
0,10 M HCl, pl 100 500 500
Sonication Time, sec 21 21 21 0
*The brain homogenate was prepared by sonicating 5 brains in
5.00 ml of 1.0 M HCl for 20 sec/brain.
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Table 4.7. To obtain the percent recovery of 5-HT in the 
presence of brain, the difference between peak heights for 
samples from group 1 and group 2 are compared to those of 
group 4. For the percent recovery of NM-5-HT in the presence 
of tissue, the peak heights for samples from either group 1 
or group 2 are compared with those of group 4. To obtain 
the percent recovery of either 5-HT or NM-5-HT in the absence 
of brain, peak heights for samples from group 3 are compared 
to those from group 4. The results are presented in Table 
4.8.
The ratio in the absence of brain tissue (1.02) is 
not much different from 1.00. But, the individual compon­
ents involved obviously show considerable losses due to 
sonication. Thus, sonication of standards was deleted from 
the procedure. The tissue samples, however, must be 
sonicated to effect homogenization. Thus, the final results 
for 5-HT assays must be divided by 0.929 (or multiplied 
by 1/0.929 =1.08) to obtain accurate values. This adjust­
ment of results is necessitated by the ratio of the percent 
recoveries for 5-HT and NM-5-HT.
E. Linearity. The 5-HT concentration-electrode response 
relationship has been tested before (2,3,4) to demonstrate 
linearity over a wide range of concentration. In all these 
studies, however, the samples used were either standard 
solutions or solutions obtained after the purification
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TABLE 4.8
Percent Recovery of 5-HT and NM-5-HT in the 




With Brain Tissue 85.1±5.8% 91.6±1.6% 0.929
Without Brain Tissue 78.9+2.7% 77.2±3.0% 1.02
by solvent extraction or ion exchange adsorption/desorption.
To ascertain that samples obtained from simple deproteinization 
contained no interfering materials, an investigation of 
linearity was undertaken. The samples used in this investiga­
tion were prepared as described for group 1 in Table 4.7 
with a variable concentration of added 5-HT. As can be seen 
from Figure 4.5, an excellent linearity is obtained over 
a wide range of added 5-HT values.
F. Final Procedure. Using the procedure described in 
the Materials and Methods section, a typical assay yielded 
a value for whole mouse brain 5-HT of 784±20 ng/g. This 
is in good agreement with the previously reported values 
listed in Table 4.2.



















Added 5 - H T  I n g / m l )
The Peak Height Ratio of 5-HT to NM-5-HT 
versus the Amount of 5-HT Added to the 
Brain Homogenate.
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is rather stable. This provides a very low noise level 
and enables the detection limit to be minimized. For example, 
an injected amount of 0.1 pmol of 5-HT clearly produced a 
peak height which was two times the noise level. This is 
comparable to the detection limit obtained by previously 
reported LC/EC procedures (2,3,11).
IV. Examination of Possible post mortem Alterations of 
Serotonin in Mouse Brain
In an examination of the possible post mortem de­
gradation of 5-HT in mouse brain, microwave irradiation (10) 
was employed to sacrifice the animals. This technique 
rapidly inactivates the metabolic enzyme monoamine oxidase 
and the biosynthetic enzymes tryptophan hydroxylase and 
5-hydroxytryptophan decarboxylase. The 5-HT levels of 
microwave treated animals is then compared to those from 
decapitated animals to detect any rapid inactivation effects. 
Animals from a third group are microwaved 5 minutes after 
decapitation to eliminate the possibility of any microwave 
artifacts. One such investigation provided the results 
presented in Table 4.9. As expected, the t-test indicates 
there is no difference between the decapitated and decapitated/ 
microwaved samples (p >0.05) while the decapitated and 
microwaved samples are significantly different, (p <0.02).
These results indicate that a rapid post mortem degradation 
of 5-HT does, indeed occur. These results further indicate
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TABLE 4.9
5-HT Levels of Whole Mouse Brain After Sacrificing by 
Microwave Irradiation and Decapitation




the lack of any instrument-related artifacts. But, at the 
present time, we have not been able to obtain results that 
are consistent in these microwave studies. This is most 
clearly seen in the results obtained for seven mouse brain 
parts (see Table 4.10 and 4.11).
The results listed here indicate that the microwaved 
samples generally have a higher 5-HT level than those from 
decapitated animals, suggesting a rapid post mortem degradation 
does occur. But the decapitated/microwaved samples, in 
most cases, have lower 5-HT levels than either the decapitated 
or microwaved samples. Instrumental artifacts should have 
produced a value for this combined result which would have 
been equivalent to the microwaved samples. No artifacts 
should produce results for the combined samples which are 
indiscernible from decapitated animals. The source of this 
discrepancy is not currently understood.
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TABLE 4.10
5-HT Levels of Mouse Brain Parts After Different 
Methods of Sacrificing








Diencephalon 838+72 331+43 1,222+41
Hippocampus 543±29 330±71 896±23
Striatum 598±45 436±88 710±32
Midbrain 809+54 297±48 1,356±39
Cortex 560±32 288±64 755+20
Cerebellum 72 + 9 68±14 338±13
Medulla-Pons 343±61 141±54 690+88
TABLE 4.11
T-Test for Results Listed in Table 4.10
Brain Parts T-Test (P-values) *
D v s . d /m D vs. M D/M vs. M
Diencephalon <0.001 0.002 <0.001
Hippocampus 0.03 <0.001 <0.001
Striatum N.S. N.S. 0.02
Midbrain <0.001 <0.001 <0.001
Cortex 0.005 <0.001 <0.001
Cerebellum N.S. N.S. <0.001
Medulla-Pons 0.04 0.02 <0.001
*N.S. indicates no significant difference.
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